



**Vaccines and Global Health: The Week in Review**  
**3 July 2021 :: Issue 614**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 23,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS  
Editor and  
Executive Director  
Center for Vaccine Ethics & Policy  
[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).

***Support this knowledge-sharing service:*** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.

**Contents** [click on link below to move to associated content]

- A. Milestones :: Perspectives :: Featured Journal Content
- B. Emergencies
- C. [WHO; CDC \[U.S., Africa, China\]](#)
- D. [Announcements](#)
- E. [Journal Watch](#)
- F. [Media Watch](#)

## ***Milestones :: Perspectives :: Research***

:::::

:::::

### **6 million children benefitting from the first ever multi-antigen vaccination campaign**

[Zimbabwe] Harare, 1 July 2021 – UNICEF, Gavi, the Vaccine Alliance and WHO have partnered with the Ministry of Health and Child Care to launch a new vaccine campaign introducing typhoid conjugate vaccine (TCV) into the routine immunisation schedule across the country.

The TCV campaign, the first of its kind in the region, was made possible through funding from Gavi and the multi-donor Health Development Fund (HDF) supported by the European Union, the United Kingdom, Sweden, Irish Aid and Gavi.

“Before the discovery of antibiotics, typhoid would kill as many as one in five people who contracted it,” said Thabani Maphosa, Managing Director of Country Programmes at Gavi. “The rise of extreme drug resistant typhoid risks bringing us back to levels of mortality not seen since the 19th century, posing a risk to all of us. That’s why typhoid conjugate vaccine is so important and why the government of Zimbabwe deserves praise for introducing this lifesaver into its routine immunisation programme.”

**The campaign has integrated TCV with the inactivated polio vaccine (IPV) and human papillomavirus (HPV) vaccination. In addition, children aged 6 to 59 months received a vitamin A supplementation.** After the initial campaign, TCV will be administered routinely to all children at 9 months of age to protect them from typhoid fever which has become endemic in Zimbabwe with outbreaks continuing to affect communities, particularly children...

Inadequate water sanitation and hygiene infrastructure and persistent water shortages particularly in urban hotspots such as Harare exacerbate the spread of typhoid. **In addition, there has been an upsurge in antimicrobial resistance to *Salmonella typhi* which makes it difficult and expensive to treat typhoid.**

Funding from Gavi and HDF covered the procurement of vaccines, distribution, and installation of cold chain equipment to ensure that vaccines are kept under required storage conditions, UNICEF played an integral role in ensuring that caregivers and communities are aware of the benefits of vaccines.

WHO, UNICEF and the Government empowered Village Health Workers (VHW) across the country to advocate for and educate communities, and encourage caregivers to access vaccinations for children. VHWs have become a critical stakeholder in the Expanded Program on Immunisation...

:::::

:::::

## **Malaria – China**

### **From 30 million cases to zero: China is certified malaria-free by WHO**

30 June 2021 *News release*

Following a 70-year effort, China has been awarded a malaria-free certification from WHO – a notable feat for a country that reported 30 million cases of the disease annually in the 1940s.

"Today we congratulate the people of China on ridding the country of malaria," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Their success was hard-earned and came only after decades of targeted and sustained action. With this announcement, China joins the growing number of countries that are showing the world that a malaria-free future is a viable goal."

China is the first country in the WHO Western Pacific Region to be awarded a malaria-free certification in more than 3 decades. Other countries in the region that have achieved this status include Australia (1981), Singapore (1982) and Brunei Darussalam (1987).

"Congratulations to China on eliminating malaria," said Dr Takeshi Kasai, Regional Director, WHO Western Pacific Regional Office. "China's tireless effort to achieve this important milestone demonstrates how strong political commitment and strengthening national health systems can result in eliminating a disease that once was a major public health problem. China's achievement takes us one step closer towards the vision of a malaria-free Western Pacific Region."

Globally, [40 countries and territories](#) have been granted a malaria-free certification from WHO – including, most recently, El Salvador (2021), Algeria (2019), Argentina (2019), Paraguay (2018) and Uzbekistan (2018)...

#### *Keys to success*

China provides a basic public health service package for its residents free of charge. As part of this package, all people in China have access to affordable services for the diagnosis and treatment of malaria, regardless of legal or financial status.

Effective multi-sector collaboration was also key to success. In 2010, 13 ministries in China – including those representing health, education, finance, research and science, development, public security, the army, police, commerce, industry and information technology, customs, media and tourism – joined forces to end malaria nationwide.

In recent years, the country further reduced its malaria caseload through a strict adherence to the timelines of the "1-3-7" strategy. The "1" signifies the one-day deadline for health facilities to report a malaria diagnosis; by the end of day 3, health authorities are required to confirm a case and determine the risk of spread; and, within 7 days, appropriate measures must be taken to prevent further spread of the disease...

:::::::  
:::::::

#### **HIV, TB, Malaria**

#### [\*\*WHO and Global Fund Sign Cooperation Agreement to Scale Up HIV, TB and Malaria Interventions and Strengthen Health Systems\*\*](#)

30 June 2021 *News release*

The World Health Organization and the Global Fund to Fight AIDS, Tuberculosis and Malaria signed a **cooperation and financing agreement to implement 10 strategic initiatives to accelerate the end of AIDS, tuberculosis and malaria as epidemics and strengthen systems for health.**

This new agreement, which will cover the 2021-2023 implementation period, aims to address some of the persistent challenges that impede progress against the three diseases and protect hard-won gains from new pandemics like COVID-19.

**In 2019, a total of 1.4 million people died from tuberculosis and an estimated 409,000 people died from malaria. In 2020, 690,000 people died from AIDS-related illnesses.**

**Through the new agreement, the strategic initiatives seek to:**

- Expand TB preventive treatment for people living with HIV in 9 countries across Africa;
- Strengthen efforts to provide differentiated HIV service delivery;
- Accelerate efforts to find people with TB missed by health systems in 20 countries;
- Accelerate introduction of innovation for multi-drug resistant TB treatment through regional operational research in Eastern and Central Europe;
- Support 26 countries and territories to eliminate malaria by 2025;
- Improve country data collection and use to develop evidence-informed policy;
- Foster the rapid uptake of service delivery innovations with South to South Learning;
- Improve quality of care;
- Encourage rapid uptake of procurement and supply chain management innovation; and
- Increase program sustainability, facilitate the transition to domestic financing and improve program efficiency.

WHO and the Global Fund have a long and successful partnership working together to scale up HIV, TB and malaria interventions and strengthen health systems in many countries. Through focused efforts and catalytic investments, this collaboration has contributed to significantly reduce the disease burdens of HIV, TB and malaria worldwide, saving millions of lives since 2002...

:::::  
:::::

## **COVID**

### ***Editor's Note:***

As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive. If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review all suggestions and consider for inclusion in a subsequent edition:

[david.r.curry@ge2p2global.org](mailto:david.r.curry@ge2p2global.org)

**We are seeking access to modelling which engages scenarios and articulates imperatives around a pandemic end-game through at least a 2025 horizon.** We assess that WHO must be conducting or contracting for such modeling – or should recognize an imperative to be doing so in its

global health governance role. If we have missed such modeling in progress, we would be delighted to be advised of it and will include it in our coverage.

:::::  
:::::

## **World Bank, IMF, WHO, WTO heads call for urgent action to accelerate global vaccine access**

30 June 2021

The heads of the World Bank Group, International Monetary Fund, World Health Organization and the WTO convened on 30 June the first meeting of the Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics for Developing Countries. David Malpass, Kristalina Georgieva, Dr Tedros Adhanom Ghebreyesus and Dr Ngozi Okonjo-Iweala said urgent action is needed to stop the rising human toll due to the pandemic and halt further divergence in the economic recovery between advanced economies and the rest. Following the meeting, they issued a joint statement:

### ***Joint statement***

"As many countries are struggling with new variants and a third wave of COVID-19 infections, accelerating access to vaccines becomes even more critical to ending the pandemic everywhere and achieving broad-based growth. We are deeply concerned about the limited vaccines, therapeutics, diagnostics, and support for deliveries available to developing countries. Urgent action is needed now to arrest the rising human toll due to the pandemic, and to halt further divergence in the economic recovery between advanced economies and the rest.

We have formed a Task Force, as a "war room" to help track, coordinate and advance delivery of COVID-19 health tools to developing countries and to mobilize relevant stakeholders and national leaders to remove critical roadblocks — in support of the priorities set out by World Bank Group, IMF, WHO, and WTO including in the joint statements of June 1 and June 3, and in the IMF staff's \$50 billion proposal.

At today's first meeting, we discussed the urgency of increasing supplies of vaccines, therapeutics, and diagnostics for developing countries. We also looked at practical and effective ways to track, coordinate and advance delivery of COVID-19 vaccines to developing countries.

### **As an urgent first step, we are calling on G20 countries to**

- (1) embrace the target** of at least 40 percent in every country by end-2021, and at least 60 percent by the first half of 2022,
- (2) share more vaccine doses now**, including by ensuring at least 1 billion doses are shared with developing countries in 2021 starting immediately,
- (3) provide financing**, including grants and concessional financing, to close the residual gaps, including for the ACT-Accelerator, and
- (4) remove all barriers to export of inputs and finished vaccines**, and other barriers to supply chain operations.

**In addition, to enhance transparency we agreed to compile data on dose requests (by type and quantity), contracts, deliveries (including through donations), and deployments of COVID-19 vaccines to low and middle-income countries** — and make it available as part of a shared country-level dashboard. We also agreed to take steps to address hesitancy, and to coordinate

efforts to address gaps in readiness, so countries are positioned to receive, deploy and administer vaccines."

:::::

### **WTO technical symposium feeds into continuing efforts to deal with COVID-19 pandemic**

29 June 2021

The WTO held a technical symposium on 29 June 2021 to address the main challenges to vaccine supply chain and regulatory transparency in the context of COVID-19. Representatives of the medical and pharmaceutical industry, international organizations and the WTO Secretariat explored new ways to cooperate towards finding practical solutions to scale up the global COVID-19 response and address gaps in the global production and distribution of vaccines, personal protective equipment and other medical technologies...

Panellists called for the WTO to step up its critical role in working with others to defeat the pandemic, stressing that it could look at the entire ecosystem relevant for ramping up manufacturing, transferring technology and know-how, and maintaining the free flow of vaccines, inputs and other technologies...

:::::

### **A Declaration from Members of the World's Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property**

June 24, 2021

*[Text-bolding from original]*

We, the undersigned CEOs of global biotechnology companies and associations have a social responsibility to work with other stakeholders – healthcare providers, governments, multilateral organizations, and non-governmental donor organizations – to ensure that COVID vaccines and treatments get to the patients in the world who most need them. We are working hard to fulfill this responsibility.

**:: Our sector must continue to play a constructive, proactive part in developing COVID solutions and the global manufacturing capacity to produce them.** In the past year, over 950 global R&D projects have been launched on COVID vaccines, treatments, and biologics, as companies have diverted efforts from other projects [i]. 70 percent of these projects are by small and medium sized companies [ii]. Over 250 global partnerships have been formed to build manufacturing capacity [iii]. And we are working hard to do more.

**:: Intellectual property is the foundation of our sector.** It is responsible for creating the global biotech network that responded so quickly to the COVID crisis in the first place. It is what gives investors the confidence to fund companies with long time horizons and high risks. It gave companies the assurance that they could quickly pivot during the early days of the pandemic into COVID projects. And it helped ensure the type of global cooperation and partnerships that are driving companies, countries, and manufacturers to quickly scale up the production.

**:: We support strong, collaborative efforts like those endorsed by the G-20** [iv] to address the global imbalances in access to COVID vaccines and treatments. Success will require national governments to address legislative or contractual impediments to supplying populations in need, especially in low- and middle- income countries. Bottlenecks and shortages in global supply chains for

vaccine production need to be urgently addressed. And strained health-care systems in low-and middle-income countries need significant support to ensure vaccines get to people.

**:: The proposed “waiver” of intellectual property rights proposed in the World Trade Organization (WTO) will be ineffective and counterproductive** in addressing this crisis.

Intellectual property rights are not responsible for the imbalance in COVID vaccine supplies between higher and lower income countries. It will create a long contentious global negotiation that will not urgently address the crisis, and foster more “vaccine nationalism,” exacerbating shortages in an already strained global supply chain. It would divert limited resources from companies that are focused on maximizing current global partnerships while maintaining quality and patient safety. Lastly, it would send a powerful signal to the biotech sector and investors to avoid taking the risks to develop solutions in future public health emergencies.

:: Current estimates are that existing **global vaccine manufacturers will produce more than 11 billion doses of COVID vaccines in 2021** [v], and significantly more in the first part of 2022. We are committed to working with other global stakeholders to see that these doses get to those that most need them, wherever they may be.

*List of signatories at title link above*

*Endnotes*

i Biotechnology Innovation Organization, COVID -19 Biotracker, <https://www.bio.org/policy/human-health/vaccines-biodefense/coronavirus/pipeline-trackerink>

ii Ibid.

iii List of Global Vaccine Partnerships, [https://www.bio.org/sites/default/files/2021-05/Industry\\_Partnerships\\_on\\_COVID\\_BIO.pdf](https://www.bio.org/sites/default/files/2021-05/Industry_Partnerships_on_COVID_BIO.pdf)

iv [https://global-health-summit.europa.eu/rome-declaration\\_en](https://global-health-summit.europa.eu/rome-declaration_en)

v [https://www.bio.org/sites/default/files/2021-05/Airfinity\\_production.pdf](https://www.bio.org/sites/default/files/2021-05/Airfinity_production.pdf)

::::::

:::::

**World Bank Financing for COVID-19 Vaccine Rollout Exceeds \$4 Billion for 50 Countries**

WASHINGTON, June 30, 2021 – The World Bank announced today that it is providing over \$4 billion for the purchase and deployment of COVID-19 vaccines for **51 developing countries, half of which are in Africa**. More than half of the financing comes from the International Development Association (IDA), the Bank’s fund for the world’s poorest countries, and is **on grant or highly concessional terms**. This financing is part of the Bank’s commitment to help low- and middle-income countries acquire and distribute vaccines and strengthen their health systems.

**The World Bank reiterated its call to governments, pharmaceutical companies, and organizations involved in vaccine procurement and delivery to help increase transparency and build greater public information regarding vaccine contracts, options and agreements; vaccine financing and delivery agreements; and doses delivered and future delivery plans. It asked those countries anticipating excess vaccine supplies in the coming months to release their surplus doses and options as soon as possible, in a transparent manner, to developing countries with adequate distribution plans in place.**

Since the start of the COVID-19 pandemic, the World Bank Group has approved more than \$150 billion to fight the health, economic, and social impacts of the pandemic. Since April 2020, the Bank has scaled up its financing by over 50 percent, helping more than 100 countries meet emergency health needs, strengthen pandemic preparedness, while also supporting countries as they protect the poor and jobs, and jump starting a climate-friendly recovery.

"The World Bank is helping developing countries in every region of the world with vaccine purchase and rollout," said Axel van Trotsenburg, World Bank Managing Director of Operations. "Significant challenges still remain regarding vaccine deployment and hesitancy. We are taking action on all fronts to tackle these challenges, working in solidarity with international and regional partners to expedite doses to as many people as possible and to enhance disease surveillance, preparedness, and response."

Full details of World Bank vaccine operations are posted on our [vaccine operations portal](#), with regular updates. The \$4 billion is supporting COVID-19 vaccination efforts in Afghanistan, Bangladesh, Benin, Cabo Verde, Cambodia, Comoros, the Republic of Congo, Côte d'Ivoire, Democratic Republic of Congo, Ecuador, El Salvador, Eswatini, Ethiopia, The Gambia, Georgia, Ghana, Guinea, Guinea Bissau, Guyana, Honduras, Indonesia, Jordan, Kenya, Kosovo, the Kyrgyz Republic, Lao PDR, Lebanon, Lesotho, Madagascar, Malawi, Moldova, Mongolia, Mozambique, Nepal, Niger, Pakistan, Papua New Guinea, Philippines, Rwanda, São Tomé e Príncipe, Senegal, Sierra Leone, South Sudan, Sri Lanka, Sudan, Tajikistan, Togo, Tunisia, Ukraine, Yemen, and Zambia.

The Bank's vaccine finance package is designed to be flexible. It can be used by countries to acquire doses through COVAX, the Africa Vaccine Acquisition Task Team (AVATT) or other sources. It also finances vaccine deployment and health system strengthening, such as vaccine cold-chains, training health workers, data and information systems, and communications and outreach campaigns to key stakeholders which are crucial to ensure vaccination acceptance. The Bank has aligned its eligibility criteria for COVID-19 vaccines with the revised eligibility criteria of COVAX and other multilateral partners.

The World Bank is [partnering with the African Union](#) and the World Bank-supported Africa Center for Disease Control to support AVATT initiative with resources to allow countries to purchase and deploy vaccines for up to 400 million people across Africa. **The Bank is also convening a task force with the IMF, WHO, WTO, and other partners to track, coordinate, and advance delivery of COVID-19 vaccines to developing countries.**

**The Bank continues to work with governments and partners (UNICEF, the Global Fund, WHO, and GAVI) to assess the readiness of over 140 developing countries to deploy vaccines.** Countries have made good progress since the publication of the effort's first [report](#). Latest findings show that **95 percent of countries have developed national vaccination plans, 79 percent have safety measures in place, and 82 percent have prioritizations of populations to receive the vaccine. However, only 59 percent have developed plans to train the large number of vaccinators needed and less than half have a plan in place to generate public confidence, trust, and demand for COVID-19 vaccines.**

::::::

**World Bank Vaccine Operations Portal**

<https://www.worldbank.org/en/who-we-are/news/coronavirus-covid19/world-bank-support-for-country-access-to-covid-19-vaccines>

### **Countries receiving World Bank support for vaccines**

As of July 1, 2021

This list of countries, project documents, and procurement notices and contracts at the link above will be updated as data becomes available.

::::::

::::::

### **COVID Vaccines – Migrants, Refugees, “people on the move”**

#### **Blind spots continue to prevent access to COVID-19 vaccines for refugees and migrants, new Red Cross and Red Crescent report says**

Geneva, 30 June 2021 – New research conducted by the Red Cross Red Crescent Global Migration Lab across more than 50 countries reveals that refugees and migrants continue to face serious obstacles in accessing COVID-19 vaccines. Despite some progress made in policy, the equitable inclusion of refugees and migrants in vaccination strategies and plans is far from universal.

The new study, [\*Sight Unseen: A vision for effective access to COVID-19 vaccines for migrants\*](#), takes stock of current global trends in migrants’ access to COVID-19 vaccines and builds on findings of an earlier report released in March 2021 by the Red Cross Red Crescent Global Migration Lab on the impact of COVID-19 on migrants’ access to essential services. Research draws on publicly available data from a wide range of sources, including academic institutions, governments, the United Nations, media and civil society organizations and is complemented by insights and cases studies from a survey of 52 National Red Cross and Red Crescent Societies working directly with migrants and host communities around the world.

Francesco Rocca, President of the International Federation of Red Cross and Red Crescent Societies (IFRC), said: “While some progress has been made on paper to include all migrants in vaccination strategies and plans, research insights indicate that – in practice – some groups, particularly undocumented migrants, are still left out. Ensuring everyone has access to COVID-19 vaccines is not just the right thing to do from a humanitarian perspective; it is also the smart thing to do from a health and socio-economic standpoint.”

Across the global survey, National Red Cross and Red Crescent Societies identified the following main barriers to migrants’ access to COVID-19 vaccines: 90% of respondents pointed to limited information about where and how to get the vaccine; 80% to vaccine hesitancy due to fears of side effects; 67% to language; 60% to lack of required documentation; 50% to fears of arrest, detention or deportation; 50% to limited vaccine supply; and 33% to complex registration processes...

::::::

#### **UNAIDS, IOM: People on the move living with HIV must have access to COVID-19 vaccines**

30 June 2021

Migrants, refugees, internally displaced as well as **crisis-affected and mobile populations who are living with HIV must have equitable access to COVID-19 vaccines**, said the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the International Organization for Migration (IOM).

People on the move are often more vulnerable to diseases, including COVID-19 and HIV. In addition, people living with and/or affected by HIV and migrants often experience significant inequalities. They frequently face health hazards due to sometimes perilous migration processes, substandard living situations, dangerous working conditions, as well as general lack of information, stigma, discrimination and isolation. Migrants and displaced people also face a great number of administrative, financial, geographic, social and cultural obstacles in accessing health care with regularity or continuity of care across borders – including access to HIV treatment.

**During the pandemic, against a backdrop of rising xenophobia and discrimination, some migrants living with HIV found themselves facing a triple stigma related to (1) testing positive for COVID-19, (2) having a positive HIV status, and (3) being a migrant, all of which also often had serious negative consequences on their mental health.** For many migrants and displaced persons living with HIV and other autoimmune diseases, or at risk of contracting HIV, risk exposure went up while availability of HIV services went down.

"To end inequalities and get the global response to HIV on-track to reach the 2030 target of ending AIDS as a public health threat, we must act immediately to reduce the inequalities experienced by migrants and mobile populations. This includes full access to HIV prevention and treatment services and to COVID-19 vaccines," said Winnie Byanyima, Executive Director of UNAIDS ahead of the 48th UNAIDS Programme Coordinating Board Meeting taking place next week in Geneva, Switzerland. A progress report on HIV services for migrant and mobile populations as well as refugees and crisis-affected populations will be presented at the meeting.

**"Both the global AIDS response and the COVID-19 response are leaving millions of people behind, including many migrants and forcibly displaced persons,"** stated IOM Director General António Vitorino. "We've seen that neglecting the health needs of marginalized groups can be devastating for communities. Together, all countries should pledge not to let it happen again."...

**IOM and UNAIDS urgently call on governments to take concrete action to ensure that national COVID-19 vaccination campaigns include all migrants with co-morbidities such as HIV, in line with WHO's prioritization recommendations, and that every effort is made to remove the barriers many of them still face in accessing health services, including stigma and discrimination...**

:::::  
:::::

### **Vaccine Passports et al**

#### **EU Digital COVID Certificate enters into application in the EU**

*Press release 1 July 2021*

As of today, the EU Digital COVID Certificate Regulation enters into application. This means that EU citizens and residents will now be able to have their Digital COVID Certificates issued and verified across the EU. 21 Member States as well as Norway, Iceland and Liechtenstein had [already started to issue certificates](#) ahead of today's deadline, and five EU countries are starting today.

The Commission's work on the EU Digital COVID Certificates was led by Commissioner Didier Reynders in close cooperation with Vice-Presidents Vera Jourová and Margaritis Schinas and Commissioners Thierry Breton, Stella Kyriakides, and Ylva Johansson.

Welcoming the entry into application of the EU Digital COVID Certificate, President Ursula von der Leyen said: "The European Union is delivering for its citizens. The European Digital COVID Certificate is a symbol of an open and safe Europe that is opening cautiously putting the protection of the health of our citizens first. In March, we promised to have an EU-wide system to facilitate free and safe travel within the EU by the summer holidays. Now we can confirm that the EU Digital COVID Certificate system is up and running. A vast majority of EU Member States are already connected to the system and ready to issue and verify the Certificates. More than 200 million certificates have already been generated. We are helping Europeans get back the freedom they value and cherish so much."

#### *EU Digital COVID Certificate*

The aim of the EU Digital COVID Certificate is to facilitate safe and free movement in the EU during the COVID-19 pandemic. All Europeans have the right to free movement, also without the certificate, but the certificate will facilitate travel, helping to exempt holders from restrictions such as quarantine.

The EU Digital COVID Certificate will be accessible for everyone and it:

- :: covers COVID-19 vaccination, test and recovery;
- :: is free of charge and available in all EU languages;
- :: is available in a digital and paper-based format;
- :: is secure and include a digitally signed QR code;

Under the new rules, Member States must refrain from imposing additional travel restrictions on holders of an EU Digital COVID Certificate, unless they are necessary and proportionate to safeguard public health.

In addition, the Commission committed to mobilising €100 million under the Emergency Support Instrument to support Member States in providing affordable tests...

::::::

#### **Joint COVAX statement on the equal recognition of vaccines**

GENEVA/NEW YORK/OSLO, 1 July 2021 – "COVAX was built on the principle of equitable access to COVID-19 vaccines to protect the health of people all across the globe. That means protecting their lives and livelihoods, including their ability to travel and conduct trade. **As travel and other possibilities begin to open up in some parts of the world, COVAX urges all regional, national and local government authorities to recognise as fully vaccinated all people who have received COVID-19 vaccines that have been deemed safe and effective by the World Health Organization and/or the 11 Stringent Regulatory Authorities (SRAs) approved for COVID-19 vaccines**, when making decisions on who is able to travel or attend events.

"Any measure that only allows people protected by a subset of WHO-approved vaccines to benefit from the re-opening of travel into and with that region would effectively create a two-tier system, further widening the global vaccine divide and exacerbating the inequities we have already seen in the distribution of COVID-19 vaccines. It would negatively impact the growth of economies that are already suffering the most.

**"Such moves are already undermining confidence in life-saving vaccines that have already been shown to be safe and effective, affecting uptake of vaccines and potentially putting billions of people at risk.** At a time when the world is trying to resume trade, commerce and travel, this is counter-effective, both in spirit and outcome.

"COVAX commends countries that have already shown commitment to equity as well as safety by accepting travelers protected by all vaccines validated by WHO Emergency Use Listing (EUL) and/or the 11 Stringent Regulatory Authorities (SRAs) approved for COVID-19 vaccines. We call on other nations and regions to do the same."

::::::

### **Product eligibility under the COVAX Facility**

Version dated: 29 December 2020

Products procured and/or supplied under the COVAX Facility must be quality assured to ensure positive impact on the population that receive them and to preserve the trust that has been placed in the Facility. Information about these products should be available to member states to enable them to make quick decisions on their importation and/or use and facilitate their continuous monitoring and oversite.

To achieve this, the COVAX Facility should only consider:

1. products listed by WHO Emergence Use Listing (EUL) or Prequalification (PQ) or,
2. under exceptional circumstances, products approved by a Stringent Regulatory Authority (SRA), hereunder to include Australia-TGA; EU-EMA; Canada-Health Canada; Switzerland-Swissmedic; UK-MHRA and USA-FDA....*[Background information follows]*

::::::

::::::

### **COVID Vaccines – OCHA::: HDX**

#### **COVID-19 Data Explorer: Global Humanitarian Operations**

#### **COVID-19 Vaccine Roll-out**

**Jul 03, 2021** | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

**Global COVID-19 Figures: 182M total confirmed cases; 4.0M total confirmed deaths**

**Global vaccines administered: 3.13B**

Number of Countries: 26 [26]

COVAX First Allocations (Number of Doses): 73M [73M]

COVAX Delivered (Number of Doses): 17M [15M]

Other Delivered (Number of Doses): 49M [37M]

Total Delivered (Number of Doses): 66M [52M]

Total Administered (Number of Doses): 54M [46M]

::::::

::::::

### **Coronavirus [COVID-19] - WHO**

*Public Health Emergency of International Concern (PHEIC)*  
<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

### ***Weekly Epidemiological and Operational updates***

*Last update: 2 Jul 2021*

<b>Confirmed cases ::</b>	182 319 261	[week ago: 179 686 071]
<b>Confirmed deaths ::</b>	3 954 324	[week ago 3 899 172]
<b>Vaccine doses administered:</b>	2 950 104 812	[week ago: 2 624 733 776]

::::::

### **Weekly operational update on COVID-19 - 28 June 2021**

#### *Overview*

In this edition of the COVID-19 Weekly Operational Update, highlights of country-level actions and WHO support to countries include:

- Building critical care capacities for COVID-19 in Iraq
- Building infection prevention control capacity in Azerbaijan
- Supporting South African consortium to establish first COVID mRNA vaccine technology transfer hub
- Adapting the global Strategic Preparedness and Response Plan 2021 to reinforce the collective response in the WHO Eastern Mediterranean Region
- Public Health Laboratories knowledge sharing webinars and online learning opportunities in Viet Nam
- Progress on a subset of indicators from the SPRP 2021 Monitoring and Evaluation Framework
- Updates on WHO's financing to support countries in SPRP 2021 implementation and provision of critical supplies


### **Weekly epidemiological update on COVID-19 - 29 June 2021**

#### *Overview*

In the past week, the number of new COVID-19 cases remained similar to the previous week, and the number of new deaths continued to decrease, with over 2.6 million new cases and 57 000 new deaths reported globally. This is the lowest weekly mortality figure since those recorded in early November 2020. Globally, COVID-19 incidence remains very high, with [an](#) average of over 370 000 cases reported each day over the past week. The cumulative number of cases reported globally now exceeds now 180 million and the number of global deaths is almost 4 million. This week, the African region recorded a sharp increase in incidence (33%) and mortality (42%) when compared to the previous week. All Regions, with the exception of the African Region, reported a decline in the number of new deaths in the past week.

In this edition, a special focus update on the variants is provided, along with the geographical distribution of variants of concern (VOCs) Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2). This edition also includes an overview of current challenges in the context of the COVID-19 pandemic, as well as a summary of the WHO global conference on communicating science during health emergencies.

**Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 27 June 2021\*\***



**Table 2: SARS-CoV-2 Variants of Concern (VOCs) and Variants of Interest (VOIs), as of 29 June 2021**

WHO label	Pango lineage	GISAID clade	Nextstrain clade	Earliest documented samples	Date of designation
<b>Variants of Concern (VOCs):</b>					
Alpha	B.1.1.7	GRY (formerly GR/501Y.V1)	20I (V1)	United Kingdom, Sep-2020	18-Dec-2020
Beta	B.1.351	GH/501Y.V2	20H (V2)	South Africa, May-2020	18-Dec-2020
Gamma	P.1	GR/501Y.V3	20J (V3)	Brazil, Nov-2020	11-Jan-2021
Delta	B.1.617.2	G/478K.V1	21A	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021
<b>Variants of Interest (VOIs):</b>					
Epsilon	B.1.427/ B.1.429	GH/452R.V1	21C	United States of America, Mar-2020	5-Mar-2021
Zeta	P.2	GR/484K.V2	20B	Brazil, Apr-2020	17-Mar-2021
Eta	B.1.525	G/484K.V3	21D	Multiple countries, Dec-2020	17-Mar-2021
Theta	P.3	GR/1092K.V1	21E	Philippines, Jan-2021	24-Mar-2021
Iota	B.1.526	GH/253G.V1	21F	United States of America, Nov-2020	24-Mar-2021
Kappa	B.1.617.1	G/452R.V3	21B	India, Oct-2020	4-Apr-2021
Lambda	C.37	GR/452Q.V1	20D	Peru, Dec-2020	14-Jun-2021

.....

::::::

## Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 26 June 2021

For 22 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[Update posted 02 July 2021; click on the link above for full scale view]

		Vaccines		Guidance Document 02 July 2021					
--	--	----------	--	-----------------------------------	--	--	--	--	--

### Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
1.	 Pfizer BIONTECH	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized	31/12/2020
							✓	Finalized: - Baxter Oncology GmbH Germany (DP)	30/06/2021
							✓	Diluent suppliers: - Pfizer Perth, Australia - Fresenius Kabi, USA	18 June 2021
							Additional sites, awaited : • Polymun Scientific, Austria (DP) • Pharmacia & Upjohn, Kalamazoo (DP) • mibe (Dermapharm), Germany (DP)	• Submission awaited • Submission awaited • Submission awaited	18 June 2021
2.	 AstraZeneca	AZD1222	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Core data finalized	16 April 2021
							✓	Data for Covax sites expected in April 2021 onwards	Finalized: SK-Catalent Wuxi (DS) Chemo Spain
									16 April 2021 30 April 2021 04 June 2021
3.	 AstraZeneca	AZD1222	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Other sites Finalized	As submitted 15 Feb 2021
4.	 SERUM INSTITUTE OF INDIA PVT LTD. Covishield Group	Covishield (ChAdOx1-nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
5.	 Janssen Infectious Diseases & Vaccines	Ad26.COV2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	✓	Core data finalized (US +NL sites)	12 March 2021
							✓	Additional sites: - Aspen RSA (DP) - Catalent Aagnani Italy (DP) - Merck, Durham, UK (DS) - Merck, West Point/PA (DP)	- Finalized - Ongoing - Future submission - Future submission
									-25 June 2021 - 02 July 2021 - As submitted - As submitted
6.	 moderna	mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized	30 April 2021
							✓	Additional sites, awaited: - ModernaTx, Norwood (DS) - Catalent Indiana, LLC (DP) - Lonza Biologics, Inc. Portsmouth, USA (DS) - Baxter, Bloomington, USA (DP)	- Ongoing - Ongoing - Ongoing - Ongoing
									- As submitted - As submitted - As submitted - As submitted

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
7.	 Sinopharm / BIBP <sup>1</sup>	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCorv)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized	07 May 2021
8.	 Sinovac	COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac <sup>TM</sup>	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized	01 June 2021
9.	 THE GAMALEYA NATIONAL CENTER	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings have been and continue to be held.	"Rolling" submission of clinical and CMC data has started.	Additional data (Non-CLIN, CLIN, CMC) Required. Following up on inspection observations.	Anticipated date will be set once all data is submitted and follow-up of inspection observations completed.
10.	 AstraZeneca	AZD1222	Japan MHLW/PMDA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	Submission from AZ received on 15 June, MHLW submitted review and GMP reports on 16 June 2021 and June 22.	Several meetings held separately with AZ and MHLW/PMDA	✓	Ongoing	Anticipated date: Week of 05 July
11.	 AstraZeneca	AZD1222	Australia TGA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	Submission from AZ received on 11 June	Several meetings held separately with AZ and TGA	✓	Ongoing	Anticipated date: Week of 05 July
12.	 CamSino Bio	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data starting July 2021		
13.	Bharat Biotech, India	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/COVAXIN	DCGI	Whole-Virion Inactivated Vero Cell	✓	✓	Rolling data starting July 2021		
14.	 Novavax	NVX-CoV2373/Covovax	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓	✓			
15.	 Sinopharm / WIBP <sup>2</sup>	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	✓	✓			
16.	 Curevac	Zorocimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/CV07050101	EMA	mrNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	Planned for 28 July 2021			
17.	Sanofi Pasteur	CoV2 pre5 dTM-AS03 vaccine	EMA	Recombinant, adjuvanted	✓	Planned for 9 July 2021			
18.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
19.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	Response to 2 <sup>nd</sup> EOI sent 29 Jan 2021. Additional information requested.				
20.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
21.	Clover Biopharmaceuticals	SCB-2019	EMA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	In discussion on submission strategy and timelines				

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
22.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus Abdala	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Mump	Awaiting information on strategy and timelines for submission.				

1. Beijing Institute of Biological Products Co Ltd  
2. Wuhan Institute of Biological Products Co Ltd

\* Dossier Submission dates; more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.

\*\*Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant; 4. Risk-benefit decision 5. Final decision made.

\*\*\* Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.



## COVID Vaccine Developer/Manufacturer Announcements [relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

### AstraZeneca Press Releases

#### Vaxzevria induced immunity for at least one year following a single dose and strong immune responses following either a late second dose or a third dose

28 June 2021

A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose.

The results, published by the University of Oxford on the [pre-print server of The Lancet](#), demonstrated that antibody levels remain elevated from baseline for at least one year following a single dose...

## **First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated**

27 June 2021

*Trial to enrol approximately 2,250 adults to assess safety and immunogenicity of AZD2816 against the SARS-CoV-2 virus*

The first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 were vaccinated today to assess its safety and immunogenicity in both previously vaccinated and unvaccinated adults.

The trial will recruit approximately 2,250 participants across UK, South Africa, Brazil and Poland. AZD2816 will be administered to individuals who have previously been fully vaccinated with two doses of Vaxzevria or an mRNA vaccine, at least three months after their last injection. In non-vaccinated individuals, AZD2816 will be given as two doses, four or twelve weeks apart, or given as a second dose following a first dose of Vaxzevria four weeks apart.

AZD2816 has been designed using the same adenoviral vector platform as Vaxzevria, with minor genetic alterations to the spike protein based on the Beta (B.1.351, South African) variant.

Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: "It is important we continue to stay ahead of genetically distinct variants of the coronavirus. AZD2816 should help broaden individuals immune response against emerging variants of concern. Initiating the Phase II/III trial for AZD2816 means we can be prepared should a variant vaccine be required in the future."...

**BioCubaFarma** – Cuba

Últimas Noticias

## **Recibe la vacuna cubana SOBERANA 02 autorizo de uso de emergencia en la República Islámica de Irán**

01/07/2021 19:45:41

[google translate: Cuban vaccine SOVEREIGN 02 receives authorization for emergency use in the Islamic Republic of Iran]

**CanSinoBIO**

News - No new digest announcements identified

**Clover Biopharmaceuticals** - China

News

Jun 30,2021 **Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover's COVID-19 Vaccine for the COVAX Facility**

Jun 30,2021 **Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate**

**Curevac [Bayer Ag – Germany]**

News

June 30, 2021

**CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60**

- Unique pivotal study conducted in 10 countries in fast changing variant environment; 15 COVID-19 variant strains present for efficacy analysis; original strain almost completely absent
- Statistical success criteria for primary endpoint met on basis of 228 adjudicated cases
- Vaccine efficacy of 48% against COVID-19 of any severity across all age groups and 15 variants
- Significant vaccine efficacy demonstrated in participants aged 18 to 60 and across all 15 variants:
- Efficacy of 53% against disease of any severity
- Efficacy of 77% against moderate and severe disease
- Full protection against hospitalization or death
- CureVac in ongoing dialogue with EMA; continuing regulatory submission

### **Gamaleya National Center**

[Latest News and Events](#) - No new digest announcements identified [See Russia/RFID below]

### **IMBCAMS, China**

[Home](#) - Receiving 502 Bad Gateway message upon inquiry

### **Janssen/JNJ**

[Press Releases](#)

Jul 01, 2021 United States

#### [Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response](#)

- Demonstrated strong neutralizing antibody activity against the Delta (B.1.617.2) variant
- Persistent immune responses through at least eight months

### **Moderna**

[Press Releases](#)

July 1, 2021

#### [Moderna Announces Recipharm Site in France Manufacturing COVID-19 Vaccine Moderna Following Approval by European Medicines Agency](#)

June 29, 2021

#### [Moderna Announces Emergency Use Authorization for its COVID-19 Vaccine Granted by Government of India](#)

June 29, 2021

#### [Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant First Identified in India](#)

- Serum samples from eight participants obtained one week after second dose of the primary series in the Phase 1 clinical trial of the Moderna COVID-19 Vaccine
- Serum neutralization assays performed on emerging variants including 2 additional versions of the Beta variant (B.1.351) and 3 lineage variants of B.1.617, including the Kappa (B.1.617.1) and Delta (B.1.617.2) variants

### **Novavax**

[Press Releases](#)

**[Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine](#)**

Jun 30, 2021

*-Publication of final analysis highlights the robust safety and efficacy data of NVX-CoV2373 in large, pivotal placebo-controlled trial*

...The manuscript published today in NEJM, 'Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine,' provides the final trial analysis, building on an initial interim analysis conducted in January 2021, and the updated analysis announced in March 2021, while additional data from the study was subsequently shared in preprint server medRxiv in May 2021. Today's publication may be accessed [here](#).

**[Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants: Updated June 30, 2021](#)**

Jun 30, 2021

The participation of volunteers in clinical trials is critical to medical research, and Novavax is grateful to those who stepped forward to advance COVID-19 vaccine development to help create a safer future for all. Novavax firmly believes that clinical trial participants should not be disadvantaged with respect to providing proof of vaccination. We are actively supporting authorities working to provide proof of vaccination for all who volunteered in our pivotal Phase 3 clinical trials...

**Pfizer**

[Recent Press Releases](#) - No new digest announcements identified

**Sanofi Pasteur**

[Press Releases](#)

June 29 2021 [Press releases](#)

**[Sanofi launches dedicated vaccines mRNA Center of Excellence](#)**

- Approximately €400million investment annually to accelerate end-to-end R&D of next-generation vaccines, fully financed through resource reallocation
- Focus on innovating mRNA vaccines beyond pandemic to routine use in diseases with high unmet need
- Expected minimum of six clinical candidates by 2025

**Serum Institute of India**

[NEWS & ANNOUNCEMENTS](#) - No corporate announcements identified

[Last media release still posted dated February 15, 2021; media release of April 21, 2021 apparently removed]

**Sinopharm/WIBPBIBP**

[News](#) - Website not responding at inquiry

**Sinovac**

[Press Releases](#)

**[The Lancet Inf. Dis. Published Data from Sinovac's Phase I/II Study, World's First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children](#)**

21/07/02

## Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

## Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

::::::

## GSK

Press releases for media - No new digest announcements identified

## SK Biosciences

Press releases

### [SK Bioscience Submitted Phase 3 IND for COVID-19 Vaccine](#)

2021. 06. 28

- GBP510 submitted for Phase 3 clinical study in Korea and extend to multi-country studies
- The COVID-19 vaccine to be supplied globally through COVAX Facility, if proven to be safe and effective.

::::::

::::::

## [UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 3 Jul 2021](#)

An overview of information collected from publicly announced bilateral and multilateral supply agreements [Agreements view since last week's edition]



17

vaccines **approved for use** by at least one national regulatory authority<sup>1</sup>



7

vaccines in WHO's **Emergency Use Listing**



14.6bn

doses **secured globally**



\$2 - \$40

reported vaccine **price range per dose**



3.86bn

doses **secured & optioned through COVAX**<sup>2</sup>



89.8M

doses **shipped through COVAX to 133 countries**

Deal date	Recipient	Deal type	Vaccine name	Vaccine developer	Manufacturer
6/16/2021	Equatorial Guinea	Bilateral	Sinopharm (Beijing)		Beijing Institute of Biological Products (CNBG)
6/16/2021	USA	Bilateral	Moderna		Moderna
6/20/2021	Peru	Bilateral	Sinopharm (Beijing)		Beijing Institute of Biological Products (CNBG)
6/25/2021	Donations to COVAX		Unknown		Unknown




## Duke – Launch and Scale Speedometer

### TRACKING COVID-19 VACCINE PURCHASES ACROSS THE GLOBE

[accessed 03 July 2021]

Confirmed Number of Doses Purchased by Country Income Level Classification




## Our World in Data

### Coronavirus (COVID-19) Vaccinations

## Daily COVID-19 vaccine doses administered per 100 people, Jul 2, 2021

Shown is the rolling 7-day average per 100 people in the total population. For vaccines that require multiple doses, each individual dose is counted.

Our World  
in Data



Source: Official data collated by Our World in Data – Last updated 3 July 2021, 13:00 (London time)

[OurWorldInData.org/coronavirus](https://OurWorldInData.org/coronavirus) • CC BY


► Dec 3, 2020

Jul 2, 2021

## COVID-19 vaccine doses administered per 100 people, Jul 2, 2021

For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses per 100 people can be higher than 100.

Our World  
in Data



Source: Official data collated by Our World in Data – Last updated 3 July 2021, 13:00 (London time)  
[OurWorldInData.org/coronavirus](https://OurWorldInData.org/coronavirus) • CC BY

► Dec 2, 2020


Jul 2, 2021

## Share of the population fully vaccinated against COVID-19, Jul 2, 2021

Our World  
in Data

Share of the total population that have received all doses prescribed by the vaccination protocol. This data is only available for countries which report the breakdown of doses administered by first and second doses.

[+ Add country](#)



Source: Official data collated by Our World in Data – Last updated 3 July 2021, 13:00 (London time)  
[OurWorldInData.org/coronavirus](http://OurWorldInData.org/coronavirus) • CC BY

► Dec 27, 2020

○ Jul 2, 2021



## U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Vaccines and Related Biological Products Advisory Committee

:: No meetings scheduled



### **White House [U.S.]**

Briefing Room – Selected Major COVID Announcements

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

July 01, 2021 • Press Briefings

### **U.S. COVID-19 GLOBAL RESPONSE AND RECOVERY FRAMEWORK**

July 1, 2021 :: 12 pages

The White House

*Executive Summary*

More than 600,000 of our fellow Americans, and nearly 4 million people globally, have died due to COVID-19. The devastating impact of the pandemic has been felt at home and abroad, triggering health and economic crises. Globally, we are witnessing the first wide scale increase in extreme poverty in more than twenty years, the loss of decades of development progress, increases in gender-based violence, rising food insecurity, and increased unemployment—particularly among young people and

women. Even as we gain confidence in United States (U.S.) domestic COVID-19 vaccination coverage, none of us are safe until all of us are safe. The risk of emergent, dangerous variants where COVID-19 transmission remains high poses a risk to us all. This disease knows no borders.

The U.S. will work with our partners to intensify the fight against COVID-19 around the world, pave the way to global recovery, and build back better national and global health security. Our first goal is to end the pandemic—at home and abroad. On January 21, 2021, President Biden released the [National Strategy for the COVID-19 Response and Pandemic Preparedness](#), including Goal 7, which details the Biden-Harris Administration’s comprehensive plan to restore U.S. leadership globally and build better preparedness for future threats; re-engage with the World Health Organization (WHO) and seek to strengthen and reform it; urge the international COVID-19 public health and humanitarian response; restore U.S. leadership to the international COVID-19 response and advance global health security and diplomacy; and build better biopreparedness and expand resilience for biological threats.

In support of that strategy, the U.S. COVID-19 Global Response and Recovery Framework provides a focused set of objectives and lines of effort under which U.S. departments of agencies are executing a whole-of-government response. This response aims to shorten the lifespan of and ultimately end the COVID-19 pandemic globally; mitigate its wider harms to people and economies and support the global recovery; and build back better to strengthen international readiness for future biological threats. The U.S. Government will pursue five objectives under the U.S. COVID-19 Global Response and Recovery Framework that together constitute a comprehensive approach to managing the immediate global health crisis and ending the pandemic.

The U.S. COVID-19 Global Response and Recovery Framework also supports U.S. commitments to the [G7+ Plan to Defeat the COVID-19 Pandemic in 2022 and Prevent the Next Pandemic](#) by supporting vaccination of the world’s most vulnerable populations, supporting last mile vaccination and getting shots in arms, providing personal protective equipment (PPE) and medical supplies where needed, strengthening supply, improving disease surveillance and early warning, supporting recovery, building resilience, and advancing global health security.

## **GOALS OF THE U.S. COVID-19 GLOBAL RESPONSE AND RECOVERY FRAMEWORK**

### *Overarching Goal:*

*End the pandemic; mitigate its wider harms to people and societies; and strengthen the global recovery and readiness for future pandemic threats*

### *OBJECTIVES*

1. Accelerate widespread and equitable access to and delivery of safe and effective COVID-19 vaccinations
2. Reduce morbidity and mortality from COVID-19, mitigate transmission, and strengthen health systems, including to prevent, detect, and respond to pandemic threats
3. Address acute needs driven by COVID-19, mitigate household shocks, and build resilience
4. Bolster economies and other critical systems under stress due to COVID-19 to prevent backsliding and enable recovery
5. Strengthen the international health security architecture to prevent, detect, and respond to pandemic threats

The U.S. cannot do this alone: we will partner with governments, international organizations, philanthropies, nonprofits, the private sector, and -most critically -on the frontlines with affected communities worldwide...

:::::::  
:::::::

## Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### European Medicines Agency

News & Press Releases •

#### [News: Increased manufacturing capacity for COVID-19 Vaccine Janssen \(new\)](#)

CHMP, Last updated: 02/07/2021

#### [News: Use of antibiotics in animals is decreasing \(new\)](#)

Last updated: 30/06/2021

#### [News: Update of EU recommendations for 2021–2022 seasonal flu vaccine composition \(new\)](#)


CHMP, Last updated: 28/06/2021

:::::::

### European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

*Latest Updates*




### Total doses administered in EU/EEA countries

EU EU/EEA

Cumulative uptake of at least one dose among adults (18+) in EU/EEA	Cumulative uptake of full vaccination among adults (18+) in EU/EEA
61.2%	39.7%

Number of adults (18+) with at least one dose in EU/EEA	Number of full vaccinations among adults (18+) in EU/EEA
226,667,288	147,269,602

### Progress in the vaccine uptake among adults (18+) in EU/EEA countries as of 2021-07-03



<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

::::::

### European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Press release 1 July 2021

### [EU Digital COVID Certificate enters into application in the EU](#)

As of today, the EU Digital COVID Certificate Regulation enters into application. This means that EU citizens and residents will now be able to have their Digital COVID Certificates issued and verified across the EU. 21 Member States as well as Norway, Iceland and Liechtenstein had [already started to issue certificates](#) ahead of today's deadline, and five EU countries are starting today.

The Commission's work on the EU Digital COVID Certificates was led by Commissioner Didier Reynders in close cooperation with Vice-Presidents Vera Jourova and Margaritis Schinas and Commissioners Thierry Breton, Stella Kyriakides, and Ylva Johansson.

Welcoming the entry into application of the EU Digital COVID Certificate, President Ursula von der Leyen said: "The European Union is delivering for its citizens. The European Digital COVID Certificate is a symbol of an open and safe Europe that is opening cautiously putting the protection of the health of our citizens first. In March, we promised to have an EU-wide system to facilitate free and safe travel within the EU by the summer holidays. Now we can confirm that the EU Digital COVID Certificate system is up and running. A vast majority of EU Member States are already connected to the system and ready to issue and verify the Certificates. More than 200 million certificates have already been generated. We are helping Europeans get back the freedom they value and cherish so much."

#### *EU Digital COVID Certificate*

The aim of the EU Digital COVID Certificate is to facilitate safe and free movement in the EU during the COVID-19 pandemic. All Europeans have the right to free movement, also without the certificate, but the certificate will facilitate travel, helping to exempt holders from restrictions such as quarantine.

The EU Digital COVID Certificate will be accessible for everyone and it:

- covers COVID-19 vaccination, test and recovery;
- :: is free of charge and available in all EU languages;
- :: is available in a digital and paper-based format;
- :: is secure and include a digitally signed QR code;

Under the new rules, Member States must refrain from imposing additional travel restrictions on holders of an EU Digital COVID Certificate, unless they are necessary and proportionate to safeguard public health.

In addition, the Commission committed to mobilising €100 million under the Emergency Support Instrument to support Member States in providing affordable tests...

*Press release 29 June 2021*

#### **COVID-19: EU helps deliver vaccines to Kosovo**

The European Union is helping Norway to deliver over 180,000 doses of COVID-19 vaccine to Kosovo, following Kosovo's request for assistance via the EU Civil Protection Mechanism.

*Questions and answers 29 June 2021*

#### **Questions and Answers: COVID-19 Therapeutics Strategy – list of 5 candidate therapeutics**

:::::::  
:::::::


#### **Africa: COVID-19 – Announcements/Regulatory Actions/Deployment**

## Africa CDC Vaccine Dashboard

### Africa Vaccinated

Vaccine Administered (Total)	(76.39% of supply)
Vaccine Administered (1 Dose)	(2.66% of population)
Vaccine Administered (2 Doses)	(1.04% of population)
Vaccination Completed	(1.07% of population)

<https://africacdc.org/covid-19-vaccination/>



Full scale, interactive dashboard available at: <https://africacdc.org/covid-19-vaccination/>



### Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

#### Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

[\*\*Sputnik V has demonstrated 97.8% efficacy against COVID cases and 100% efficacy against severe cases of COVID in UAE\*\*](#)

Press release, 29.06.2021

:::::  
:::::

## India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :  
03 JULY 2021, 08:00 IST  
(GMT+5:30)

(↑ Status change since  
yesterday)

Active (1.62%)

495533 (14104↓)

Discharged (97.06%)

29605779 (57477↑)

Deaths (1.31%)

401050 (738↑)

COVID-19 Vaccination  
as on : 03 July 2021,  
08:00 IST (GMT+5:30)

Total Vaccination : 34,46,11,291 (43,99,298 ↑)

02.07.2021

### [Operational Guidance for COVID-19 Vaccination of Pregnant Women](#)

### Government of India – *Press Information Bureau*

[Latest Press Releases](#)

No new digest content identified.

### Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

[Press Releases](#)

No new digest content identified.

:::::  
:::::

## China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### [NMPA holds meeting to review vaccine regulatory quality management system](#)

2021-06-25

The National Medical Products Administration (NMPA) held a vaccine regulatory quality management system review meeting on June 15, to summarize the construction and operation of the system, evaluate its appropriateness, effectiveness and adequacy, and make arrangements for the key tasks of the next stage of its construction...

### [China-UK drug regulatory cooperation project kicks off](#)

2021-06-21

The meeting adopted the plan for the China-UK drug regulatory cooperation project in 2021 to push forward technical exchanges in areas of drug review, inspection and post-marketing monitoring for better mutual understanding and deeper cooperation....



## Emergencies

### **POLIO**

*Public Health Emergency of International Concern (PHEIC)*

#### **Polio this week as of 29 June 2021**

- :: In October 2020, the Fourth meeting between the National Authorities for Containment (NAC) and Containment Working Group for the Global Commission for Certification (GCC-CWG) was convened to discuss global updates on the Containment workstream programme, COVID-19 implications and Containment programme adjustments, among other issues. The meeting report is now available [here](#).
- :: "For global programs to meet their goals and improve health, gender must be addressed at every level, from the household and community to management and organizational leadership."- Conclusion in the recently published research: The influence of gender dynamics on polio eradication efforts. Read more [here](#).

***Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):***

- :: Nigeria: ten cVDPV2 cases and four cVDPV2 positive environmental samples
- :: Egypt: one cVDPV2 positive environmental sample



*Note for the record*

#### **Fourth Meeting between the National Authorities for Containment and Containment Working Group for the Global Commission for Certification**

Virtual Meeting -Tuesday, Wednesday 27-28 October 2020

##### *Contents*

- :: Abbreviations and acronyms
- :: Update on global poliovirus containment –Daphne Moffett, WHO
- :: Update on the auditor qualification and auditor support plan, 2021–2023 –Nicoletta Previsani, WHO
- :: Process for revision of the Global Action Plan for Poliovirus Containment (GAPIII, 2014) and development of a tool for identifying and assessing potentially infectious materials and poliovirus – Harpal Singh, WHO
- :: Next steps towards certification of containment –James Blaine, Chair, Containment Working Group Task Group
- :: Status of containment certification –David Salisbury, Chair, Global Commission for the Certification of the Eradication of Poliomyelitis
- :: Outcomes of the survey of national authorities for containment –Harpal Singh, WHO
- :: Application for a certificate of participation: lessons learnt and the way forward –Liliane Boualam, WHO
- :: Country experience –Lia Haynes Smith, US National Authority for Poliovirus Containment, USA
- :: Requirements for containment of novel oral poliovirus vaccine and potentially of S19 –Mark Pallansch, Chair, Advisory Group on mOPV2 provision
- :: The way forward –Daphne Moffett, WHO

:::::  
:::::

## **WHO/OCHA Emergencies**

### ***Editor's Note:***

*WHO has apparently reorganized and fundamentally shifted how it judges and tracks "emergencies". We found no announcement of descriptive information to share and present the webpage structure as encountered below. Obviously, the dates associated with some of these emergencies suggest that this is an archival platform as well as a current emergencies resource.*

### **Health emergencies list - WHO**

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

#### **Ebola outbreak, Democratic Republic of the Congo, 2021**

*[Last apparent update: 3 May 2021]*

#### **Ebola outbreak outbreak, N'Zerekore, Guinea, 2021** *[Last apparent update: 3 May 2021]*

#### **Coronavirus disease (COVID-19) pandemic** *[Last apparent update 3 July 2021; See COVID above]*

#### **Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020** *[Last apparent update: 1 June 2021]*

#### **Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020** *[Last apparent update: 3 May 2021]*

#### **Ebola outbreak, Democratic Republic of the Congo, 2018** *[Last apparent update: 24 July 2018]*

#### **Yemen crisis** *[Last apparent update: 12 February 2021]*

#### **Syria crisis** *[Last apparent update: 18 June 2021]*

#### **Somalia crisis** *[Last apparent update: 24 March 2018]*

#### **Nigeria crisis** *[Last apparent update: 9 May 2018]*

#### **Ebola outbreak, Democratic Republic of the Congo, 2017** *[Last apparent update: 3 May 2021]*

#### **Zika virus disease outbreak, 2015-2016** *[Last apparent update: 24 Jan 2020]*

#### **Ebola outbreak: West Africa, 2014-2016** *[Last apparent update: 3 May 2021]*

#### **Iraq crisis** *[Last apparent update: 9 Jan 2008]*

[\*\*South Sudan crisis\*\*](#) *[Last apparent update: 23 Sep 2020]*

[\*\*Avian influenza A \(H7N9\) virus outbreak\*\*](#) *[Last apparent update: 21 May 2021]*

[\*\*Middle East respiratory syndrome \(MERS-CoV\) outbreak\*\*](#) *[Last apparent update: 8 July 2019]*

[\*\*Influenza A \(H1N1\) virus, 2009-2010 pandemic\*\*](#) *[Last apparent update: 10 Aug 2010]*

::::::

### [\*\*UN OCHA – Current Emergencies\*\*](#)

*Current Corporate Emergencies*

*No new digest content identified*

::::::

::::::

**WHO & Regional Offices** [to 3 Jul 2021]

<https://www.who.int/>

1 July 2021

Joint News Release

[\*\*Billions of people will lack access to safe water, sanitation and hygiene in 2030 unless progress quadruples – warn WHO, UNICEF\*\*](#)

1 July 2021

Statement

[\*\*Joint COVAX Statement on the Equal Recognition of Vaccines\*\*](#)

1 July 2021

Departmental news

[\*\*New training resources to help young people support one another during emergencies\*\*](#)

30 June 2021

Departmental news

[\*\*The first Newsletter of the Global Chemicals and Health Network\*\*](#)

30 June 2021

News release

[\*\*WHO and Global Fund Sign Cooperation Agreement to Scale Up HIV, TB and Malaria Interventions and Strengthen Health Systems\*\*](#)

30 June 2021

Statement

[\*\*First Meeting of the Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics for Developing Countries\*\*](#)

30 June 2021

Statement

**Joint Statement by the Heads of the World Bank Group, International Monetary Fund, World Health Organization, and World Trade Organization on the First Meeting of the Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics for Developing Countries**  
[See COVID above for detail]

30 June 2021

Departmental news

**WHO launches List of Priority Medical Devices for management of cardiovascular diseases and diabetes**

30 June 2021

News release

**From 30 million cases to zero: China is certified malaria-free by WHO**

30 June 2021

Departmental news

**Health Workforce in COVID-19 Action Series: Time to Protect. Invest. Together.**

28 June 2021

News release

**WHO issues first global report on Artificial Intelligence (AI) in health and six guiding principles for its design and use**

::::::

**Weekly Epidemiological Record, Vol. 96, No. 26, pp. 265–280 2 July 2021**

- :: Index of countries/areas265
- :: Index, Volume 96, 2021, Nos. 1–26267
- :: Kala-azar in India – progress and challenges towards its elimination as a public health problem
- :: Monthly report on dracunculiasis cases, January-April 2021

::::::

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**WHO African Region AFRO**

- :: Leveraging lessons from Africa's COVID-19 vaccine rollout 03 July 2021

From exemplary mass-vaccination stations in Angola, to complex cold-chain logistics in Rwanda and model communications to boost trust in vaccines in Ghana, the World Health Organization (WHO) is documenting key lessons emerging from Africa's rollout of COVID-19 vaccines.

- :: Inside Angola's 'exemplary' COVID-19 vaccination hubs 02 July 2021

The Paz Flor mall is usually packed with shoppers browsing for bargains or sitting down to enjoy a meal, but as Angola's rollout of COVID-19 vaccines ramps up, the vibrant space in the nation's capital has been converted to serve up life-saving vaccines.

**WHO Region of the Americas PAHO**

*No new digest content identified*

## **WHO South-East Asia Region SEARO**

*No new digest content identified*

## **WHO European Region EURO**

- :: Small countries come together to move forward in the face of COVID-19 02-07-2021
- :: Largest disruption to schooling in history due to COVID-19 measures must not rob children of their education and development 02-07-2021
- :: COVID-19: The stakes are still high 01-07-2021
- :: An adapted alcohol screening test will help to fight health harms in the Russian Federation and beyond 01-07-2021
- :: WHO/Europe launches new monitoring tool, tracking rates of COVID-19 in UEFA Euro 2020 host cities 30-06-2021

## **WHO Eastern Mediterranean Region EMRO**

- :: Reaching people in northeast Syria with COVID-19 vaccines 29 June 2021
- :: Scaling up active surveillance for COVID-19 in Somalia 28 June 2021
- :: Working with the media to improve communication on COVID-19 vaccines in Syria 27 June 2021

## **WHO Western Pacific Region**

- :: 30 June 2021 News release From 30 million cases to zero: China is certified malaria-free by WHO

:::::  
:::::

## **CDC/ACIP [U.S.]** [to 3 Jul 2021]

<http://www.cdc.gov/media/index.html>  
<https://www.cdc.gov/vaccines/acip/index.html>  
*Latest News Releases, Announcements*

*No new digest content identified*

:::::

## **MMWR News Synopsis Friday, July 2, 2021**

- :: Prevalence of Voluntary Medical Male Circumcision for HIV Infection Prevention — Chókwè District, Mozambique, 2014–2019
- :: Symptoms of Depression, Anxiety, Post-Traumatic Stress Disorder, and Suicidal Ideation Among State, Tribal, Local, and Territorial Public Health Workers During the COVID-19 Pandemic — United States, March–April 2021 (Early Release June 25, 2021)
- :: Disparities in Learning Mode Access Among K–12 Students During the COVID-19 Pandemic, by Race/Ethnicity, Geography, and Grade Level — United States, September 2020–April 2021 (Early Release June 29, 2021)

:::::

## **Coronavirus Disease 2019 (COVID-19)- CDC**

*Approximately 50 announcements/reports/data summaries, including:*

:::::  
:::::

**Africa CDC** [to 3 Jul 2021]  
<http://www.africacdc.org/>

*No new digest content identified*

:::::  
:::::

**China CDC** <http://www.chinacdc.cn/en/>  
**CCDC Weekly - Weekly Reports: Current Volume (3)**  
2021-07-02 / No. 27  
[PDF of this issue](#)

:: [Preplanned Studies: Perception of the COVID-19 Epidemic and Acceptance of Vaccination Among Healthcare Workers Prior to Vaccine Licensure — Beijing Municipality, China, May–July 2020](#)  
:: [Preplanned Studies: Integrated Approaches for COVID-19 Case Finding and Their Impact on Timeliness for Disease Containment — Changning District, Shanghai Municipality, China, January–July, 2020](#)  
:: [Perspectives: Progress of Active Surveillance for Vaccine Safety in China](#)  
:: [Notes from the Field: Transmission Dynamics of an Outbreak of the COVID-19 Delta Variant B.1.617.2 — Guangdong Province, China, May–June 2021](#)  
:: [Notes from the Field: Genome Characterization of the First Outbreak of COVID-19 Delta Variant B.1.617.2 — Guangzhou City, Guangdong Province, China, May 2021](#)

**National Health Commission of the People's Republic of China** [to 3 Jul 2021]  
<http://en.nhc.gov.cn/>

*News*

[July 3: Daily briefing on novel coronavirus cases in China](#)

On July 2, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 23 new cases of confirmed infections.

[WHO: China free of malaria](#)

2021-07-01

The World Health Organization declared China free of malaria on June 30, hailing its "notable feat" of driving annual cases down from 30 million to zero in 70 years.

The WHO said China had become the first country in the Western Pacific region to eliminate the mosquito-borne disease in over three decades, after Australia, Singapore and Brunei...

[Vaccination vital to reining in delta variant of virus](#)

2021-06-29

*Infectious disease expert says strain is twice as transmissible as previous ones*

**National Medical Products Administration – PRC** [to 3 Jul 2021]  
<http://english.nmpa.gov.cn/news.html>

News

## **Over 1.2bl doses of COVID-19 vaccines administered in China**

2021-06-30

Over 1.2 billion doses of COVID-19 vaccines have been administered in China as of Monday, as the country continues to ramp up its inoculation drive, the National Health Commission said on June 29.

:::::  
:::::

## **Organization Announcements**

*Editor's Note:*

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

### **Paul G. Allen Frontiers Group [to 3 Jul 2021]**

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

*News*

*No new digest content identified.*

### **BARDA – U.S. Department of HHS [to 3 Jul 2021]**

<https://www.phe.gov/about/barda/Pages/default.aspx>

*News*

*No new digest content identified.*

### **BMGF - Gates Foundation [to 3 Jul 2021]**

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases and Statements*

*Press release*

Jun 30, 2021

### **Gates Foundation Commits \$2.1 Billion to Advance Gender Equality Globally**

*Commitments at the Generation Equality Forum will advance women's economic empowerment, strengthen health and family planning, and accelerate women in leadership as women suffer disproportionately from the pandemic*

### **Bill & Melinda Gates Medical Research Institute [to 3 Jul 2021]**

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*No new digest content identified.*

**CARB-X** [to 3 Jul 2021]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 3 Jul 2021]

<https://centerforvaccineethicsandpolicy.net/>

*News/Analysis/Statements*

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: [NEW] ***Informed Consent: A Monthly Review – July 2021*** is now posted [here](#)

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 3 Jul 2021]

<http://cepi.net/>

*Latest News*

[\*\*Joint COVAX Statement on the Equal Recognition of Vaccines\*\*](#)

COVAX 01 Jul 2021

*[See COVID above for detail]*

[\*\*From lab to potential jab: Clover's COVID-19 vaccine story\*\*](#)

CEPI's early investment in Clover has been key to accelerating development and equitable access to this promising vaccine.

COVAX 01 Jul 2021

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 3 Jul 2021]

<https://cioms.ch/>

*News; Publications*

[\*\*CIOMS June 2021 Newsletter\*\*](#)

The CIOMS June 2021 Newsletter is available [here](#).

**DARPA – Defense Advanced Research Projects Agency** [to 3 Jul 2021]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 3 Jul 2021]

<https://dukeghic.org/>

*No new digest content identified.*

**EDCTP** [to 3 Jul 2021]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

30 June 2021

**Annual Report 2020 – focused delivery on promises**

**Emory Vaccine Center** [to 3 Jul 2021]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 3 Jul 2021]

<http://www.euvaccine.eu/>

*Latest News*

*No new digest content identified*

**FDA** [to 3 Jul 2021]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

*Press Announcements / Selected Details*

**July 2, 2021 - Coronavirus (COVID-19) Update: July 2, 2021**

Today, the FDA authorized the use, under the emergency use authorization (EUA) for the Janssen COVID-19 vaccine, of an additional batch of vaccine drug substance manufactured at the Emergent facility. To date a total of four batches of Janssen drug substance that were manufactured at the Emergent facility have been authorized...

**June 29, 2021 - Coronavirus (COVID-19) Update: June 29, 2021**

The FDA has sent to Congress its [Report on Drug Shortages for Calendar Year 2020](#), which includes a section on the agency's drug shortage efforts in response to COVID-19...

**Fondation Merieux** [to 3 Jul 2021]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified*

**Gavi** [to 3 Jul 2021]

<https://www.gavi.org/>

*News Releases*

1 July 2021

**6 million children benefitting from the first ever multi-antigen vaccination campaign**

[Zimbabwe] Harare, 1 July 2021 – UNICEF, Gavi, the Vaccine Alliance and WHO have partnered with the Ministry of Health and Child Care to launch a new vaccine campaign introducing typhoid conjugate vaccine (TCV) into the routine immunisation schedule across the country.

The TCV campaign, the first of its kind in the region, was made possible through funding from Gavi and the multi-donor Health Development Fund (HDF) supported by the European Union, the United Kingdom, Sweden, Irish Aid and Gavi.

“Before the discovery of antibiotics, typhoid would kill as many as one in five people who contracted it,” said Thabani Maphosa, Managing Director of Country Programmes at Gavi. “The rise of extreme drug resistant typhoid risks bringing us back to levels of mortality not seen since the 19th century, posing a risk to all of us. That’s why typhoid conjugate vaccine is so important and why the government of Zimbabwe deserves praise for introducing this lifesaver into its routine immunisation programme.”

**The campaign has integrated TCV with the inactivated polio vaccine (IPV) and human papillomavirus (HPV) vaccination. In addition, children aged 6 to 59 months received a vitamin A supplementation.** After the initial campaign, TCV will be administered routinely to all children at 9 months of age to protect them from typhoid fever which has become endemic in Zimbabwe with outbreaks continuing to affect communities, particularly children...

1 July 2021

**Joint COVAX Statement on the equal recognition of vaccines**

[See COVID above for detail]

30 June 2021

**Indonesia introduces Pneumococcal Conjugate Vaccine (PCV) across the country**

:: Gavi, UNICEF and partners collaborate on nationwide introduction, which will see all children from the age of two months protected from pneumonia by 2022

:: The country has received 1.6 million doses of the vaccine procured through the Gavi Pneumococcal Advanced Market Commitment mechanism

:: Anuradha Gupta: “Congratulations to the Government of Indonesia on this milestone, which will save the lives of thousands of children across the country for years to come”

30 June 2021

**Gavi signs agreement with Clover Biopharmaceuticals for supply to COVAX**

:: The signed advance purchase agreement (APA) will make up to 414 million doses of the Clover vaccine candidate available to the COVAX Facility, pending WHO Emergency Use Listing (EUL)

:: Supply will be available to self-financing participants of the COVAX Facility as well as lower-income economies eligible to be supported by the Gavi COVAX Advance market Commitment (AMC), expected to commence Q4 2021

27 June 2021

**US-donated vaccine deliveries through COVAX set to begin, with first shipment to Honduras**

:: Deliveries of US-donated doses through COVAX to begin today

:: Anticipated delivery of the Moderna vaccine to Honduras comes after announcements by President Biden of significant dose-sharing pledges; further deliveries to follow in coming days and weeks

**GHIT Fund** [to 3 Jul 2021]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.*

**Global Fund** [to 3 Jul 2021]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*News*

**[WHO and Global Fund Sign Cooperation Agreement to Scale Up HIV, TB and Malaria Interventions and Strengthen Health Systems](#)**

30 June 2021

The World Health Organization and the Global Fund to Fight AIDS, Tuberculosis and Malaria signed a cooperation and financing agreement to implement 10 strategic initiatives to accelerate the end of AIDS, tuberculosis and malaria as epidemics and strengthen systems for health. This new agreement, which will cover the 2021-2023 implementation period, aims to address some of the persistent challenges that impede progress against the three diseases and protect hard-won gains from new pandemics like COVID-19.

In 2019, a total of 1.4 million people died from tuberculosis and an estimated 409,000 people died from malaria. In 2020, 690,000 people died from AIDS-related illnesses...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 3 Jul 2021]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 3 Jul 2021]

<http://www.hillemanlabs.org/>

*Website reports "under maintenance" at inquiry*

**Human Vaccines Project** [to 3 Jul 2021]

<http://www.humanvaccinesproject.org/>

*News*

*News webpage not responding at inquiry*

**IAVI** [to 3 Jul 2021]

<https://www.iavi.org/newsroom>

*Latest News*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICRC** [to 3 Jul 2021]

<https://www.icrc.org/en/whats-new>

*Selected News Releases, Statements, Reports*

**Sexual Violence, Conflict, and COVID-19: An Invisible Pandemic**

Despite clear legal prohibitions, sexual violence remains widespread during armed conflicts and other situations of violence, as well as in detention. It occurs in various contexts and has grave humanitarian consequences.

24-06-2021 | Article

**The challenges for humanitarian action in today's conflicts: the perspective from the International Committee of the Red Cross**

Excellencies, colleagues. It is a pleasure to address you today and I extend my warm appreciation to Minister of Defence Sergey Shoygu.

23-06-2021 | Statement

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 3 Jul 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

*Africa*

**As COVID-19 cases surge in Africa, Red Cross warns that insufficient funding is impeding the response**

Nairobi/Geneva, 2 July 2021 – Halting an increasing trend of COVID-19 cases in Africa will require additional funding. This was announced by the International Federation of Red Cross and Red Crescent Societies (IFRC), amid a worrying surge of cases in ...

2 July 2021

**Blind spots continue to prevent access to COVID-19 vaccines for refugees and migrants, new Red Cross and Red Crescent report says**

Geneva, 30 June 2021 – New research conducted by the Red Cross Red Crescent Global Migration Lab across more than 50 countries reveals that refugees and migrants continue to face serious obstacles in accessing COVID-19 vaccines. Despite some progress in ...

30 June 2021

*Indonesia*

## **Indonesia: On edge of catastrophe as COVID-19 overwhelms hospitals**

Kuala Lumpur/Jakarta/Geneva, 29 June 2021: Urgent increases are needed in medical care, testing and vaccinations as Indonesia teeters on the edge of a COVID-19 catastrophe. The more dangerous and deadly Delta COVID-19 variant is fuelling infections tha ...

29 June 2021

### **Institut Pasteur [to 3 Jul 2021]**

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*Press Info*

01.07.2021

### **Modelling study of benefits and risks associated with the COVID-19 vaccine Vaxzevria**

On April 7, 2021, the European Medical Agency (EMA) concluded that thrombosis in combination with thrombocytopenia has...

*Press release*

29.06.2021

### **Neonatal meningitis: the immaturity of microbiota and epithelial barriers implicated**

Meningitis is associated with high mortality and frequently causes severe sequelae. Newborn infants are particularly...

### **IOM / International Organization for Migration [to 3 Jul 2021]**

<http://www.iom.int/press-room/press-releases>

*News*

### **IOM's Emergency Director Urges Swift, Durable Solutions to Protracted Rohingya Crisis**

2021-06-29 16:08

Cox's Bazar – Almost 900,000 Rohingya refugees in congested camps in Bangladesh's Cox's Bazar District desperately need urgent action to secure their future, nearly four years after they were forced to flee Myanmar, a senior International Organization for...

### **IVAC [to 3 Jul 2021]**

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

### **Johns Hopkins Launches 'Vira' Vax ChatBot**

July 2021

COVID-19 vaccination is lagging in young adults nationally. Vira, the Vax Chatbot is designed to support and meet young people where they are with simple answers to common COVID-19 vaccine questions. Vira is adaptive, learning by listening to your questions and feedback to help scientists respond to emerging questions. [...]

### **IVI [to 3 Jul 2021]**

<http://www.ivi.int/>

*Selected IVI News, Announcements, Events*

*No new digest content identified.*

**JEE Alliance** [to 3 Jul 2021]

<https://www.jeealliance.org/>

Selected News and Events

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 3 Jul 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

### **Johns Hopkins Center for Health Security Shares Recommendations to Improve Nation's Public Health and Medical Preparedness and Response Programs**

June 28, 2021 – As the U.S. Congress continues to respond to and begin recovery from the COVID-19 pandemic, they must also prepare for the next pandemic, which could appear at any time. For over 20 years, the Johns Hopkins Center for Health Security has worked to protect people's health from epidemics and disasters and ensure community resilience by examining how innovations, policies, and programs can strengthen health security.

The Center has identified 13 proposals that, if empowered through bipartisan legislation, would improve the nation's public health, and increase medical preparedness and response programs for future public health events.

*Proposals:*

- Expedite Development of Medical Countermeasures for Unknown Viral Threats
- Invest in Ongoing and Just-in-Time Social Science Research to Ensure Public Support for Outbreak Management
- Authorize the National Center for Epidemic Forecasting and Outbreak Analytics
- Prioritize Funding for Development of At-Home Diagnostic Technology
- Support Innovation and Stockpile Strategies to Provide Better Respiratory Protective Devices
- Create a National Center for Pandemic and Disaster Nursing Research
- Develop New Vaccine Delivery Platforms to Rapidly Immunize Millions in a Pandemic
- Develop a National Strategy to Combat Health-Related Misinformation and Disinformation
- Create Deployable Research Response Teams
- Create a Central Repository for Serosurveys and Public Health Observational Studies
- Evaluate the Hospital Preparedness Program's Effectiveness during the Pandemic
- Enlist the Community Health Sector in Achieving Adequate Preparedness and Response for Vulnerable Populations
- Develop a Coherent Strategy and Substructure to Facilitate Comprehensive Recovery from an Infectious Disease Disaster

[Read full summaries of the proposals.](#)

**MSF/Médecins Sans Frontières** [to 3 Jul 2021]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Coronavirus COVID-19 pandemic*

### **COVID-19 pandemic threatens to deteriorate in Brazil as 500,000 deaths recorded**

Project Update 30 Jun 2021

As the weather gets colder in Brazil and the pandemic rolls on, the COVID-19 situation in the country has again become deeply concerning, with national and international experts warning of a third devastating wave.

The response remains fragmented and decentralised while the central authorities continue to disregard science, including the importance of masks and physical distancing, in their health messaging.

Sadly, Brazilians now account for over 500,000 COVID-19 deaths and the average COVID-19 fatality rate has crept above 2,000 people a day for the first time since May. Likewise, the number of new cases has also risen to more than 70,000 a day. This is the highest average since the peak of cases during the second wave in early May...

### **National Academy of Medicine - USA [to 3 Jul 2021]**

<https://nam.edu/programs/>

*Selected News/Programs*

*No new digest content identified.*

### **National Vaccine Program Office - U.S. HHS [to 3 Jul 2021]**

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

### **NIH [to 3 Jul 2021]**

<http://www.nih.gov/news-events/news-releases>

*News Releases*

#### **NIH COVID-19 testing initiative funds additional research projects to safely return children to in-person school**

July 2, 2021 — The awards are the second installment of the Safe Return to School Diagnostic Testing Initiative.

#### **Investigational malaria vaccine gives strong, lasting protection**

June 30, 2021 — Phase 1 trials conducted at NIH Clinical Center.

Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs—an approach termed chemoprophylaxis vaccination. A Phase 2 clinical trial of the vaccine is now underway in Mali, a malaria-endemic country. If the approach proves successful there, chemoprophylaxis vaccination, or CVac, potentially could help reverse the stalled decline of global malaria. Currently, there is no vaccine in widespread use for the mosquito-transmitted disease.

The trials were conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. They were led by Patrick E. Duffy, M.D., of the NIH National Institute of Allergy and Infectious Diseases (NIAID), and Stephen L. Hoffman, M.D., CEO of Sanaria Inc., Rockville, Maryland.

The Sanaria vaccine, called PfSPZ, is composed of sporozoites, the form of the malaria parasite transmitted to people by mosquito bites. Sporozoites travel through blood to the liver to initiate infection...

## **NIH-funded screening study builds case for frequent COVID-19 antigen testing**

June 30, 2021 — Rapid antigen tests perform on par with lab tests when used every three days.

## **Adjuvant developed with NIH funding enhances efficacy of India's COVID-19 vaccine**

June 29, 2021 — Adjuvants are formulated as part of a vaccine to boost immune responses and enhance effectiveness.

**PATH** [to 3 Jul 2021]

<https://www.path.org/media-center/>

*Press Releases*

### **PATH announces new five-year strategy**

June 29, 2021—PATH announced the launch of a new strategy that will guide the organization's efforts over the next five years.

The result of a year-long development process that included input from more than 400 local stakeholders across 50 countries, [PATH Strategy 2025](#) aims to respond to current global crises, to the needs and priorities of PATH's local partners, and to their resounding call for more equitable and inclusive approaches to global public health.

"Our new strategy is very exciting, not only for PATH, but for our entire sector. Over the next five years, we will transform PATH into an even better agent of change for global health," said Nikolaj Gilbert, President and CEO of PATH.

PATH Strategy 2025 outlines three main priorities: preparing for and responding to emerging health threats, improving lives with science and technology, and increasing health system capacity and resilience.

The five-year plan also outlines four change strategies—equity in health, community-focused priorities, respectful partnerships, and inclusive innovation—that will shape how PATH approaches its work. To learn more about PATH Strategy 2025, visit [path.org/strategy2025](http://path.org/strategy2025).

## **PATH welcomes introduction of the US International Pandemic Preparedness and COVID-19 Response Act of 2021**

June 29, 2021 by PATH

**Sabin Vaccine Institute** [to 3 Jul 2021]

<http://www.sabin.org/updates/pressreleases>

*Statements and Press Releases*

*No new digest content identified.*

**UNAIDS** [to 3 Jul 2021]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

1 July 2021

### **Report shows big COVID-19-related HIV prevention programme service disruptions, but highlights that HIV service innovations and adaptations are possible**

30 June 2021

**UNAIDS, IOM: People on the move living with HIV must have access to COVID-19 vaccines**

[See COVID above for detail]

28 June 2021

### [The journey towards comprehensive sexuality education](#)

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 3 Jul 2021]

<http://www.unhcr.org/en-us/media-centre.html>

*Selected News Releases, Announcements*

#### [Refugee health challenges remain high amid COVID-19](#)

1 Jul 2021

Malaria remained the single most common cause of illness among refugees in 2020, while psychological distress caused by COVID-19, and acute malnutrition constituted major threats to refugees' health and well-being, according to data released today by UNHCR, the UN Refugee Agency, in its Annual Public Health Global Review.

In a year marked by the pandemic, UNHCR's key focus was to advocate for the inclusion of refugees in COVID-19 national response plans. The agency also worked to support national health systems by procuring personal protective equipment, other equipment like oxygen concentrators, COVID-19 tests and medicines, and by increasing intensive care capacity in countries such as Lebanon and Bangladesh...

**United Nations Human Rights Council** [to 3 Jul 2021]

[https://www.ohchr.org/EN/HRBodies/HRC/Pages/NewsSearch.aspx?NTID=PRS&MID=HR\\_COUNCIL\\_Council\\_News](https://www.ohchr.org/EN/HRBodies/HRC/Pages/NewsSearch.aspx?NTID=PRS&MID=HR_COUNCIL_Council_News)

#### [COVID, State surveillance, smartphones, mega tech-corporations and artificial intelligence are only a few of the themes which will remain recurrent throughout the life of the mandate on privacy](#)

02/07/2021

[Access to reliable information sources is the obvious antidote to disinformation, Special Rapporteur on freedom of opinion and expression tells Human Rights Council](#)

02/07/2021

[COVID-19 Pandemic Brought on a Substantive Setback for Persons with Leprosy who must be Recognised as a Vulnerable Group with Regard to Vaccination, Special Rapporteur Tells Human Rights Council](#)

01/07/2021

**UNICEF** [to 3 Jul 2021]

<https://www.unicef.org/media/press-releases>

*Press Releases, News Notes, Statements [Selected]*

*News note 07/01/2021*

#### [UNICEF signs COVID-19 vaccine supply agreement with Janssen Pharmaceutica NV](#)

COPENHAGEN/NEW YORK, 1 July 2021 – UNICEF has signed a long-term agreement with Janssen Pharmaceutica NV for the supply of COVID-19 vaccine on behalf of the COVAX Facility.

Through the supply agreement, UNICEF, along with procurement partners including the Pan-American Health Organization (PAHO), will have access to up to 200 million doses of the single-dose vaccine in 2021 for 92 countries supported by the Advance Market Commitment and also some self-financing countries. This is the 6th such agreement that UNICEF has completed for COVID-19 vaccines, previous agreements have been announced with the Serum Institute of India, Pfizer, AstraZeneca, Human Vaccine and Moderna...

*Press release 07/01/2021*

**Billions of people will lack access to safe water, sanitation and hygiene in 2030 unless progress quadruples – warn WHO, UNICEF**

Latest estimates reveal that 3 in 10 people worldwide could not wash their hands with soap and water at home during the COVID-19 pandemic

*Statement 07/01/2021*

**Joint COVAX statement on the equal recognition of vaccines**

*[See COVID above for detail]*

*Press release 06/30/2021*

**Indonesia introduces pneumococcal conjugate vaccine (PCV) across the country**

:: Gavi, UNICEF and partners collaborate on nationwide introduction, which will see all children from the age of two months protected from pneumonia by 2022

:: The country has received 1.6 million doses of the vaccine procured through the Gavi Pneumococcal Advanced Market Commitment mechanism

:: Anuradha Gupta: "Congratulations to the Government of Indonesia on this milestone, which will save the lives of thousands of children across the country for years to come"

*Statement 06/27/2021*

**Statement on U.S. donation of 1.5 million doses of COVID-19 vaccine to Honduras**

*Statement by Jean Gough, UNICEF Regional Director for Latin America and the Caribbean*

PANAMA CITY, 27 June 2021 - "UNICEF welcomes the first United States Government donation of COVID-19 vaccines via COVAX's dose-sharing mechanism, arriving today in Honduras, and calls for more largescale vaccine donations, in particular to hard-hit Latin America and the Caribbean.

"With only less than 62,000 Hondurans reportedly fully vaccinated, these 1.5 million doses of vaccine represent long-awaited relief to Honduras, which has one of the lowest vaccination rates in Latin America. Moreover, these doses are a glimmer of hope to the region and all countries waiting anxiously for COVAX doses. The United States should be applauded for stepping up to support Honduras, the region, and the world..."

**Unitaid** [to 3 Jul 2021]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccine Equity Initiative** [to 3 Jul 2021]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 3 Jul 2021]

<https://www.vaccineacceptance.org/>

*Announcements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 3 Jul 2021]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

**Coronavirus global impact**

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 3 Jul 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 3 Jul 2021]

<https://wellcome.ac.uk/news>

*News and reports*

*News*

**From equality to global poverty: the Covid-19 effects on societies and economies**

29 June 2021

The Covid-19 pandemic is a social and an economic crisis just as much as it is a health one – its repercussions, severe and far-reaching, are being felt across the world.

**The Wistar Institute** [to 3 Jul 2021]

<https://www.wistar.org/news/press-releases>

*Press Releases*

Jun. 29, 2021

**Wistar Scientists Discover Blood-based Biomarkers to Predict HIV Remission After Stopping Antiretroviral Therapy**

The newly identified sugar and metabolic signatures may help predict duration and probability of HIV remission after antiretroviral therapy interruption during cure-directed clinical trials.

**WFPHA: World Federation of Public Health Associations** [to 3 Jul 2021]

<https://www.wfpha.org/>

*Latest News*

**Recommendations to Drive Value-based Decision-making in Vaccination**

Jun 30, 2021

## [The Value\(S\) of Vaccination: Building the Scientific Evidence according to a Value-Based Healthcare Approach](#)

Jun 29, 2021

**World Bank** [to 3 Jul 2021]

<http://www.worldbank.org/en/news/all>

*Selected News, Announcements*

### [Over 350,000 People to Obtain COVID-19 Vaccination in Liberia](#)

WASHINGTON, June 30, 2021 – The World Bank today approved Additional Financing to the Liberia COVID-19 Emergency Preparedness and Response Project to enable affordable and equitable access to COVID-19...

Date: June 30, 2021 Type: Press Release

### [World Bank Financing for COVID-19 Vaccine Rollout Exceeds \\$4 Billion for 50 Countries](#)

WASHINGTON, June 30, 2021 – The World Bank announced today that it is providing over \$4 billion for the purchase and deployment of COVID-19 vaccines for 51 developing countries, half of which are...

Date: June 30, 2021 Type: Press Release

*[See COVID above for detail]*

### [Benin: World Bank Support for the COVID-19 Vaccination Rollout](#)

WASHINGTON, June 29, 2021 – The World Bank has approved \$30 million in additional financing from the International Development Association (IDA)\* to help Benin vaccinate its population against COVID-19...

Date: June 29, 2021 Type: Press Release

### [Sudan Gets a Boost from World Bank Group for COVID-19 Response](#)

KHARTOUM, June 29, 2021—The Government of Sudan and the World Bank signed a grant agreement of \$100 million to boost the country's COVID-19 response and expand vaccination coverage in the country. This...

Date: June 29, 2021 Type: Press Release

### [World Bank Approves \\$24 Million to Support Zambia with COVID-19 Vaccines](#)

WASHINGTON, June 29, 2021 – The World Bank approved \$24 million in additional financing to the Republic of Zambia for the acquisition and equitable distribution of COVID-19 (coronavirus) vaccines. The...

Date: June 29, 2021 Type: Press Release

## **World Customs Organization – WCO** [to 3 Jul 2021]

<http://www.wcoomd.org/>

*Latest News – Selected Items*

30 June 2021

### [WCO Deputy Secretary General addresses the WTO Technical Symposium on COVID-19 vaccine supply chain and regulatory transparency](#)

The Deputy Secretary General of the World Customs Organization (WCO), Mr. Ricardo Treviño, joined the Deputy Director-General of the World Trade Organization (WTO), Ms. Anabel González and

the Assistant Director-General of the World Health Organization (WHO), Dr. Mariângela Simão in the opening of the WTO Technical Symposium on COVID-19 vaccine supply chain and regulatory transparency that was held online on 29 June 2021.

The Technical Symposium was organized as a follow-up to the WTO event on COVID-19 and vaccine equity that was held on 14 April 2021 with the participation of the WCO Secretary General. The 29 June 2021 follow-up event was aimed at contributing to improved public and policymaker understanding of the operation of global COVID-19 vaccine supply chains, the cross-border movement of vaccine inputs, and the need for greater regulatory transparency and convergence. The Technical Symposium was also aimed at mapping vaccine production and trade and discussing trade measures that support or constrain the achievement of the rapid scale-up of vaccine production and distribution....

### **World Organisation for Animal Health (OIE) [to 3 Jul 2021]**

<https://www.oie.int/en/for-the-media/press-releases/2021/>

*Press Releases*

#### **Ten years on, Rinderpest eradication highlights the value of vaccines**

*News 28 June 2021*

The global eradication of Rinderpest gives reason to be optimistic when it comes to fighting infectious animal diseases. While the recent COVID-19 pandemic has shown the devastating impact emerging infectious diseases can have, it is also a reminder of the critical role vaccines can play in protecting us all.

*This text was originally published on the [iD4D website](#) under Creative Commons BY NC ND 4.0 International*

### **WTO - World Trade Organisation [to 3 Jul 2021]**

[http://www.wto.org/english/news\\_e/news\\_e.htm](http://www.wto.org/english/news_e/news_e.htm)

*WTO News and Events*

#### **Improving trade data for COVID-19 products key to better response policies: WTO**

*1 July 2021*

Improving trade data on products needed to combat the COVID-19 pandemic — including vaccines and their components — is key to ensuring that the right policies are in place to facilitate their distribution, according to a new information note issued by the WTO Secretariat on 1 July.

#### **WTO issues new update on trade in medical goods in the context of COVID-19**

*30 June 2021*

The WTO Secretariat has published a further update of its information note on trade in medical goods in the context of tackling COVID-19. The update provides figures on trade in medical goods covering all of 2020.

#### **World Bank, IMF, WHO, WTO heads call for urgent action to accelerate global vaccine access**

*30 June 2021*

The heads of the World Bank Group, International Monetary Fund, World Health Organization and the WTO convened on 30 June the first meeting of the Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics for Developing Countries. David Malpass, Kristalina Georgieva, Dr Tedros Adhanom Ghebreyesus and Dr Ngozi Okonjo-Iweala said urgent action is needed to stop the rising human toll

due to the pandemic and halt further divergence in the economic recovery between advanced economies and the rest. Following the meeting, they issued a joint statement.

*[See COVID above for detail]*

### **WTO technical symposium feeds into continuing efforts to deal with COVID-19 pandemic**

29 June 2021

The WTO held a technical symposium on 29 June 2021 to address the main challenges to vaccine supply chain and regulatory transparency in the context of COVID-19. Representatives of the medical and pharmaceutical industry, international organizations and the WTO Secretariat explored new ways to cooperate towards finding practical solutions to scale up the global COVID-19 response and address gaps in the global production and distribution of vaccines, personal protective equipment and other medical technologies.

*[See COVID above for detail]*

::::::

### **ARM [Alliance for Regenerative Medicine] [to 3 Jul 2021]**

Press Releases - Alliance for Regenerative Medicine (alliancerm.org)

*Selected Press Releases*

### **ARM and NIIMBL Release Project A-Gene to Bring Quality by Design Principles to Gene Therapy Manufacturing**

June 24, 2021, Washington, DC

The Alliance for Regenerative Medicine (ARM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) today released Project A-Gene, a multistakeholder collaboration to incorporate Quality by Design (QbD) principles into a manufacturing case study of a viral vector commonly used in gene therapies...

### **BIO [to 3 Jul 2021]**

<https://www.bio.org/press-releases>

*Press Releases, Letters, Testimony, Comments [Selected]*

### **BIO Letter to USTR Ambassador Tai on Global Vaccine Distribution**

June 30, 2021

We would like to provide you some updates on the U.S. and global biotechnology industry's efforts to scale-up global vaccine production to address the global imbalance in access to COVID vaccines, and to request a close working relationship with...

### **BIO letter to HHS Secretary Xavier Becerra on the importance of funding R&D for COVID-19 therapeutics at Biomedical Advanced Research and Development Agency (BARDA).**

June 25, 2021

The partnership between the biopharmaceutical industry and the U.S. Government is largely responsible for where we are with the COVID-19 pandemic today. In just 16 months from the declaration of the pandemic, cases have dramatically dropped as more...

### **A Declaration from Members of the World's Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property**

June 24, 2021

*[See COVID above for detail]*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 3 Jul 2021]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 3 Jul 2021]

<https://internationalbiotech.org/news/>

*News*

**[A Declaration from Members of the World's Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property](#)**

Jul. 01 2021

*[See COVID above for detail]*

**IFPMA** [to 3 Jul 2021]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

*No new digest content identified.*

**International Alliance of Patients' Organizations – IAPO** [to 3 Jul 2021]

<https://www.iapo.org.uk/news/topic/6>

*Press and media [Selected]*

*No new digest content identified.*

**PhRMA** [to 3 Jul 2021]

<http://www.phrma.org/>

*Latest News [Selected]*

**[3 things that support robust biopharmaceutical research and development](#)**

June 29, 2021

Let's take a closer look at three key pillars of the biopharmaceutical ecosystem that are central to the success of America's research and development:

1. Private-public collaboration
2. A robust intellectual property (IP) system
3. Strong private sector investment in R&D

\*

\*

\*

\*

**Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but

indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 12, 2020 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 23, Number 6: E435-504 June 2021

<https://journalofethics.ama-assn.org/issue/transgenerational-trauma>

#### **Transgenerational Trauma**

One thing that makes trauma transgenerational is narrative. Narrative, for example, is what makes a Confederate flag from 1865 flint for insurrection in 2021. Consequences of global and domestic insults, such as slavery and forced migration, have long ramified intergenerationally in communities, families, and individuals' bodies. Legacies of trauma travel in stories across places and over time, and their effects include health status inequity and cumulative stress embodiment. Transmission of historically entrenched patterns of oppression also influence persons' lived experiences of marginalization, convey health risk, and can play out during clinical encounters.

### **American Journal of Infection Control**

June 2021 Volume 49 Issue 6 p657-856

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

June 2021 Volume 60 Issue 6 p737-884

<http://www.ajmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

June 2021 111(6)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 104 (2021): Issue 4 (Apr 2021)

<https://www.ajtmh.org/view/journals/tpmd/104/4/tpmd.104.issue-4.xml>

[Reviewed earlier]

**Annals of Internal Medicine**

June 2021 Volume 174, Issue 6

<http://annals.org/aim/issue>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 295 June 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/295/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 3 Jul 2021)

[No new digest content identified]

**BMJ Global Health**

June 2021 - Volume 6 - 6

<https://gh.bmj.com/content/6/6>

*Editorial*

[\*\*Building resilient health systems in Africa beyond the COVID-19 pandemic response\*\*](#) (28

June, 2021)

Akalewold T Gebremeskel, Akaninyene Otu, Seye Abimbola, Sanni Yaya

[\*\*Global vaccine equity demands reparative justice — not charity\*\*](#) (21 June, 2021)

Sophie Harman, Parsa Erfani, Tinashe Goronga, Jason Hickel, Michelle Morse, Eugene T Richardson

[\*\*Going beyond access to health information: a pandemic call to action\*\*](#) (10 June, 2021)

Soumyadeep Bhaumik, Pranab Chatterjee

*Analysis*

[\*\*Ethics-driven policy framework for implementation of movement restrictions in pandemics\*\*](#)

(3 June, 2021)

Siddhesh Zadey, Surabhi Dharmadhikari, Pradeeksha Mukuntharaj

*Original research*

[\*\*Integrated health service delivery during COVID-19: a scoping review of published evidence from low-income and lower-middle-income countries\*\*](#) (16 June, 2021)

Md Zabir Hasan, Rachel Neill, Priyanka Das, Vasuki Venugopal, Dinesh Arora, David Bishai, Nishant Jain, Shivam Gupta

[\*\*Interventions to improve district-level routine health data in low-income and middle-income countries: a systematic review\*\*](#) (11 June, 2021)

Jieun Lee, Caroline A Lynch, Lauren Oliveira Hashiguchi, Robert W Snow, Naomi D Herz, Jayne Webster, Justin Parkhurst, Ngozi A Erondu

**A partisan pandemic: state government public health policies to combat COVID-19 in Brazil** (3 June, 2021)

Michael Touchton, Felicia Marie Knaul, Héctor Arreola-Ornelas, Thalia Porteny, Mariano Sánchez, Oscar Méndez, Marco Faganello, Vaugh Edelson, Benjamin Gygi, Calla Hummel, Silvia Otero, Jorge Insua, Eduardo Undurraga, Julio Antonio Rosado

**Unravelling 'low-resource settings': a systematic scoping review with qualitative content analysis** (3 June, 2021)

Chanel van Zyl, Marelise Badenhorst, Susan Hanekom, Martin Heine

**BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 3 Jul 2021)

[No new digest content identified]

**BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 3 Jul 2021)

**Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial**

*Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (...)*

Authors: Julio Vallejos, Rodrigo Zoni, María Bangher, Silvina Villamandos, Angelina Bobadilla, Fabian Plano, Claudia Campias, Evangelina Chaparro Campias, María Fernanda Medina, Fernando Achinelli, Hector Andres Guglielmone, Jorge Ojeda, Diego Farizano Salazar, Gerardo Andino, Pablo Kawerin, Silvana Dellamea...

Citation: BMC Infectious Diseases 2021 21:635

Content type: Research

Published on: 2 July 2021

**Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis**

*The introduction of human papillomavirus (HPV) vaccination has resulted in a remarkable decline of genital warts in women and men, but in Germany historical rates of vaccination are relatively low. We report (...)*

Authors: Agnieszka Denecke, Thomas Iftner, Angelika Iftner, Sebastian Riedle, Marion Ocak, Alexander Luyten, Isak Üye, Kübra Tunc and Karl Ulrich Petry

Citation: BMC Infectious Diseases 2021 21:634

Content type: Research article

Published on: 2 July 2021

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 3 Jul 2021)

### **How ethics committees and requirements are structuring health research in the Philippines: a qualitative study**

*The last few decades have seen the rising global acknowledgment of the importance of ethics in the conduct of health research. But research ethics committees or institutional review boards (IRBs) have also bee...*

Authors: Gideon Lasco, Vincen Gregory Yu and Lia Palileo-Villanueva

Citation: BMC Medical Ethics 2021 22:85

Content type: Research

Published on: 1 July 2021

### **Adherence with reporting of ethical standards in COVID-19 human studies: a rapid review**

*Patients with COVID-19 may feel under pressure to participate in research during the pandemic.*

*Safeguards to protect research participants include ethical guidelines [e.g. Declaration of Helsinki and good clin...*

Authors: Lydia O'Sullivan, Ronan P. Killeen, Peter Doran and Rachel K. Crowley

Citation: BMC Medical Ethics 2021 22:80

Content type: Research

Published on: 28 June 2021

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 3 Jul 2021)

### **Paediatric rotavirus vaccination, coeliac disease and type 1 diabetes in children: a population-based cohort study**

*Rotavirus infection has been proposed as a risk factor for coeliac disease (CD) and type 1 diabetes (T1D). The UK introduced infant rotavirus vaccination in 2013. We have previously shown that rotavirus vaccin...*

Authors: Thomas Inns, Kate M. Fleming, Miren Iturriza-Gomara and Daniel Hungerford

Citation: BMC Medicine 2021 19:147

Content type: Research article

Published on: 29 June 2021

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 3 Jul 2021)

[No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 3 Jul 2021)

### **Content analysis of digital media coverage of the human papillomavirus vaccine school-entry requirement policy in Puerto Rico**

*In August 2018, Puerto Rico (PR) became the 4th state or territory in the United States to adopt a human papillomavirus (HPV) vaccine school-entry requirement, for students 11–12 years old. Evidence suggests t...*

Authors: Vivian Colón-López, Vilnery Rivera-Figueroa, Glizette O. Arroyo-Morales, Diana T. Medina-Laabes, Roxana Soto-Abreu, Manuel Rivera-Encarnación, Olga L. Díaz-Miranda, Ana P. Ortiz, Katelyn B. Wells, Coralia Vázquez-Otero and Pamela C. Hull

Citation: BMC Public Health 2021 21:1286

Content type: Research article

Published on: 1 July 2021

### **Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis**

*Vaccine receipt among mid-adults remains low, with only one quarter of adults being up to date for all recommended vaccines. It is important to understand the myriad factors that influence vaccine receipt among...*

Authors: Mallory K. Ellingson, Carlos R. Oliveira, Sangini S. Sheth, Erin L. Sullivan, Ashlynn Torres, Eugene D. Shapiro and Linda M. Niccolai

Citation: BMC Public Health 2021 21:1283

Content type: Research

Published on: 1 July 2021

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 3 Jul 2021)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

June 2021 - Volume 26 - 3

<https://ebm.bmj.com/content/26/3>

[Reviewed earlier]

### **BMJ Open**

June 2021 - Volume 11 - 6

<https://bmjopen.bmj.com/content/11/5>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 99, Number 6, June 2021, 405-476

<https://www.who.int/bulletin/volumes/99/6/en/>

[Reviewed earlier]

### **Cell**

Jun 24, 2021 Volume 184 Issue 13 p3349-3590

<https://www.cell.com/cell/current>

[Reviewed earlier]

### **Child Care, Health and Development**

Volume 47, Issue 4 Pages: 411-574 July 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 109, Issue 6 Pages: 1363-1679 June 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

### **Clinical Therapeutics**

Volume 43 Issue 4 p651-792

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

### **Clinical Trials**

Volume 18 Issue 3, June 2021

<https://journals.sagepub.com/toc/ctja/18/2>

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 3 Jul 2021]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 105 June 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/105/suppl/C>

[Reviewed earlier]

### **The CRISPR Journal**

Volume 4, Issue 3 / June 2021

<https://www.liebertpub.com/toc/crispr/4/3>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 9, issue 2, June 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-2>  
[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

June 2021 - Volume 34 - Issue 3

<https://journals.lww.com/co-infectiousdiseases/pages/currrenttoc.aspx>  
[Reviewed earlier]

### **Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>  
[Reviewed earlier]

### **Developing World Bioethics**

Volume 21, Issue 2 June 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

***Special Issue: Conscientious objection to termination of pregnancy in the global south: legal and ethical challenges***

Issue Edited by: Anita Kleinsmidt

### **Development in Practice**

Volume 31, Issue 4, 2021

<http://www.tandfonline.com/toc/cdip20/current>  
[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 15 - Issue 2 - April 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>  
[Reviewed earlier]

### **Disasters**

Volume 45, Issue 3 Pages: 499-737 July 2021

<https://onlinelibrary.wiley.com/toc/14677717/current>  
[Reviewed earlier]

### **EMBO Reports**

Volume 22 Issue 6 4 June 2021

<https://www.embopress.org/toc/14693178/current>  
[Reviewed earlier]

**Emerging Infectious Diseases**

Volume 27, Number 7—July 2021

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

**Epidemics**

Volume 35 June 2021

<https://www.sciencedirect.com/journal/epidemics/vol/35/suppl/C>

[Reviewed earlier]

**Epidemiology and Infection**

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

**Ethics & Human Research**

Volume 43, Issue 3 Pages: 1-44 May–June 2021

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Underrepresented populations in clinical research Human infection challenge trials***

[Reviewed earlier]

**The European Journal of Public Health**

Volume 31, Issue 2, April 2021

<https://academic.oup.com/eurpub/issue/31/2>

[Reviewed earlier]

**Expert Review of Vaccines**

Vol 20 (3) 2021

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

**Forum for Development Studies**

Volume 48, 2021 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

**Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 3 Jul 2021]

[No new digest content identified]

**Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 3 Jul 2021]

[No new digest content identified]

**Global Health Action**

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**

Vol. 9, No. 2 June 30, 2021

<http://www.ghspjournal.org/content/current>

[New issue; No digest content identified]

**Global Public Health**

Volume 16, Issue 7 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

**Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 3 Jul 2021]

[No new digest content identified]

**Health Affairs**

Vol. 40, No. 5 May 2021

<https://www.healthaffairs.org/toc/hlthaff/current>

***May 2021 / Consolidation, Private Equity & More***

[Reviewed earlier]

**Health and Human Rights**

Volume 22, Issue 1, June 2020

<https://www.hhrjournal.org/volume-22-issue-1-june-2020/>

***Special Section: Mental Health and Human Rights***

[Reviewed earlier]

**Health Economics, Policy and Law**

Volume 16 - Issue 3 - July 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>  
[Reviewed earlier]

### **Health Policy and Planning**

Volume 36, Issue 5, June 2021

<https://academic.oup.com/heapol/issue/36/5>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 3 Jul 2021]

[No new digest content identified]

### **Human Gene Therapy**

Volume 32, Issue 11-12 / June 2021

<https://www.liebertpub.com/toc/hum/32/11-12>

[Reviewed earlier]

### **Humanitarian Exchange Magazine**

Number 79, May 2021

<https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/>

#### **Localisation and local humanitarian action**

*by HPN October 2020*

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 17, Issue 5, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

**Infectious Agents and Cancer**

<http://www.infectagentscancer.com/content>

[Accessed 3 Jul 2021]

[No new digest content identified]

**Infectious Diseases of Poverty**

<http://www.idpjurnal.com/content>

[Accessed 3 Jul 2021]

[No new digest content identified]

**International Health**

Volume 13, Issue 4, July 2021

<https://academic.oup.com/inthealth/issue/13/4>

*COMMENTARIES*

**[Research ethics during a pandemic \(COVID-19\)](#)**

Kheng-Wei Yeoh, Ketan Shah

The current pandemic with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a major global health crisis.<sup>1</sup> This has put tremendous strain on healthcare systems around the world and naturally raises issues concerning the allocation of scarce resources. It presents a clear and urgent need for research into management of the disease in individuals and of the epidemic in populations. Addressing this need around the world raises practical and ethical issues for the scientific research...

**International Journal of Community Medicine and Public Health**

Vol 8, No 5 (2021) May 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/76>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 50, Issue 2, April 2021

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

*Table of Contents*

[Reviewed earlier]

**International Journal of Infectious Diseases**

Volume 107 p1-310

<https://www.ijidonline.com/current>

[Reviewed earlier]

## **JAMA**

June 22/29, 2021, Vol 325, No. 24, Pages 2419-2512  
<https://jamanetwork.com/journals/jama/currentissue>  
[Reviewed earlier]

## **JAMA Network**

### **COVID-19 Update July 3, 2021**

*These articles on COVID-19 were published across the JAMA Network in the last week.*

## **JAMA Pediatrics**

June 2021, Vol 175, No. 6, Pages 553-652  
<https://jamanetwork.com/journals/jamapediatrics/currentissue>  
[Reviewed earlier]

## **JBI Evidence Synthesis**

June 2021 - Volume 19 - Issue 6  
<https://journals.lww.com/jbisrir/Pages/currrenttoc.aspx>  
[New issue; No digest content identified]

## **Journal of Adolescent Health**

Volume 68 Issue 6 p1025-1222  
<https://www.jahonline.org/current>  
[Reviewed earlier]

## **Journal of Artificial Intelligence Research**

Vol. 71 (2021)  
<https://www.jair.org/index.php/jair>  
[Reviewed earlier]

## **Journal of Community Health**

Volume 46, issue 3, June 2021  
<https://link.springer.com/journal/10900/volumes-and-issues/46-3>  
[Reviewed earlier]

## **Journal of Development Economics**

Volume 151 June 2021  
<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/151/suppl/C>  
[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 16 Issue 3, July 2021

<http://journals.sagepub.com/toc/jre/current>

*Empirical Studies on Informed Consent*

**Multicomponent Informed Consent with Marshallese Participants**

Rachel S. Purvis, Britni L. Ayers, Cari A. Bogulski, Kyle F. Kaminicki, Lauren K. Haggard-Duff, Lynda A. Riklon, Anita Iban, Rrotha Mejbon-Samuel, Rumina Lakmis, Sheldon Riklon, Joseph W. Thompson, Pearl A. McElfish

First Published March 29, 2021; pp. 144–153

**Informed Consent for Online Research—Is Anybody Reading?: Assessing Comprehension and Individual Differences in Readings of Digital Consent Forms**

Caitlin Geier, Robyn B. Adams, Katharine M. Mitchell, Bree E. Holtz

First Published May 24, 2021; pp. 154–164

*Special Topic: Ethical issues in Artificial Intelligence (AI) Research*

**Boundaries Between Research Ethics and Ethical Research Use in Artificial Intelligence Health Research**

Gabrielle Samuel, Jenn Chubb, Gemma Derrick

First Published March 18, 2021; pp. 325–337

**Journal of Epidemiology & Community Health**

June 2021 - Volume 75 - 6

<https://jech.bmjjournals.org/content/75/6>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 14, Issue 2 Pages: 83-169 May 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 16, Issue 3, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 32, Number 2, May 2021 Supplement

<https://muse.jhu.edu/issue/44396>

*Table of Contents*

**Overview of the Issue**

Kevin B. Johnson, Tiffani J. Bright, Cheryl R. Clark

...The importance of techquity—defined as the strategic development and deployment of technology in health care and health to advance health equity—was even more apparent after the events of 2020. COVID-19 upended access to care and illuminated the impact of structural racism as a cause for a widening gap of access during the pandemic. Black Lives Matter became more than a trending hashtag on Twitter, or a movement resulting in peaceful protests and calls for policy reform: it put additional focus on the issue of race as a social and not a biological construct and called into question the rationale for common practices in health care that were triggered by race. A notable example was the emerging realization that kidney function assessment was tied to race and hardwired into many of our electronic health records. The real-world evidence around our lack of techquity was incontrovertible.

This Supplemental Issue of JHCPU provides articles that describe challenges to techquity, frameworks to improve the role of technology in care, and examples of how technology can transform health, public health, and health care...

### **Journal of Immigrant and Minority Health**

Volume 23, issue 3, June 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-3>

[Reviewed earlier]

### **Journal of Immigrant & Refugee Studies**

Volume 19, 2021\_ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

### **Journal of Infectious Diseases**

Volume 223, Issue 9, 1 May 2021

<https://academic.oup.com/jid/issue/223/9>

[Reviewed earlier]

### **Journal of Medical Ethics**

June 2021 - Volume 47 - 6

<http://jme.bmjjournals.org/content/current>

[Reviewed earlier]

### **Journal of Patient-Centered Research and Reviews**

Volume 8, Issue 2 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

### **Journal of Pediatrics**

Volume 234 p1-296

<http://www.jpeds.com/current>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 3 Jul 2021]

[No new digest content identified]

**Journal of Public Health Management & Practice**

May/June 2021 - Volume 27 - Issue 3

<https://journals.lww.com/jphmp/pages/currrenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 42, issue 2, June 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-2>

[Reviewed earlier]

**Journal of Refugee & Global Health**

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

June 2021 Volume 18 Issue 179

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

**Journal of Travel Medicine**

Volume 28, Issue 4, May 2021

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

May 2021; Volume 95, Issue 10

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

Jul 03, 2021 Volume 398 Number 10294 p1-92, e1-e6

<https://www.thelancet.com/journals/lancet/issue/current>

*Lecture*

**Learning from crisis: building resilient systems to combat future pandemics**

Ilona Kickbusch, Gabriel M Leung, Robin J Shattock

COVID-19 has accelerated medical research in the quest to understand this new pandemic threat, to answer public health questions, and to develop a vaccine that could allow a return to "normal" life. A spotlight has illuminated how evidence becomes policy, and the interface of politics and science, which encompasses ecological, financial, and social risks, among others. In a lecture delivered for the Academy of Medical Sciences on Nov 2, 2020, we examined the threat of future pandemics in the light of COVID-19, reviewing how to prepare, how to build resilient health systems, and what we can learn from coronavirus to combat pandemics of the future.

**The Lancet Child & Adolescent Health**

Jun 2021 Volume 5 Number 6 p385-458, e19-e27

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

**Lancet Digital Health**

Jun 2021 Volume 3 Number 6 e330-e407

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

**Lancet Global Health**

Jun 2021 Volume 9 Number 6 e721-e879

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Jun 2021 Volume 21 Number 6 p743-888, e141-e181

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Jun 2021 Volume 6 Number 6 e346-e433

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Jun 2021 Volume 9 Number 6 p545-672, e51-e55

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

## **Maternal and Child Health Journal**

Volume 25, issue 6, June 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-6>

[New issue; No digest content identified]

## **Medical Decision Making (MDM)**

Volume 41 Issue 5, July 2021

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

## **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 99, Issue 2 Pages: 329-599 June 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

*Original Scholarship*

*Open Access*

### **International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility**

MARK ECCLESTON-TURNER, HARRY UPTON

Pages: 426-449

First Published: 02 March 2021

*Policy Points*

:: Equitable access to a COVID-19 vaccine in all countries remains a key policy objective, but experience of previous pandemics suggests access will be limited in developing countries, despite the rapid development of three successful vaccine candidates.

:: The COVAX Facility seeks to address this important issue, but the prevalence of vaccine nationalism threatens to limit the ability of the facility to meet both its funding targets and its ambitious goals for vaccine procurement.

:: A failure to adequately address the underlying lack of infrastructure in developing countries threatens to further limit the success of the COVAX Facility.

*Perspectives*

*Free Access*

### **Allocating a COVID-19 Vaccine: Balancing National and International Responsibilities**

REIDAR K. LIE, FRANKLIN G. MILLER

Pages: 450-466

First Published: 09 December 2020

*Policy Points*

:: In this paper we propose a middle-ground policy for the distribution of an effective COVID-19 vaccine, between a cosmopolitan approach that rejects entirely nation-state priority and unbridled vaccine nationalism that disregards obligations to promote an equitable global allocation of an effective vaccine over time.

:: Features of the COVAX partnership, a collaboration among the Global Alliance for Vaccines and Immunizations (GAVI), the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO) to develop and distribute COVID-19 vaccines make it an appropriate framework for a middle-ground policy.

**Nature**

Volume 595 Issue 7865, 1 July 2021

<https://www.nature.com/nature/volumes/595/issues/7865>

[New issue; No digest content identified]

**Nature Biotechnology**

Volume 39 Issue 6, June 2021

<https://www.nature.com/nbt/volumes/39/issues/6>

[Reviewed earlier]

**Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 3 Jul 2021)

[No new digest content identified]

**Nature Genetics**

Volume 53 Issue 6, June 2021

<https://www.nature.com/ng/volumes/53/issues/6>

[Reviewed earlier]

**Nature Human Behaviour**

Volume 5 Issue 6, June 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/6>

[Reviewed earlier]

**Nature Medicine**

Volume 27 Issue 6, June 2021

<https://www.nature.com/nm/volumes/27/issues/6>

[Reviewed earlier]

**Nature Reviews Genetics**

Volume 22 Issue 6, June 2021

<https://www.nature.com/nrg/volumes/22/issues/6>

[Reviewed earlier]

**Nature Reviews Immunology**

Volume 21 Issue 6, June 2021

<https://www.nature.com/nri/volumes/21/issues/6>

[Reviewed earlier]

## **Nature Reviews Drug Discovery**

Volume 20 Issue 6, June 2021

<https://www.nature.com/nrd/volumes/20/issues/6>

[Reviewed earlier]

## **New England Journal of Medicine**

July 1, 2021 Vol. 385 No. 1

<http://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

### **[Covid-19 and the Investigator Pipeline](#)**

Katrina Armstrong, M.D., M.S.C.E.

... Emerging infectious diseases and other health threats will continue to pose a danger to the United States and the global community. It's time to leverage vaccine-development efforts to take on another important Covid-related challenge: stabilizing the investigator pipeline. As recent months have shown, the scientific pipeline is both in jeopardy and central to our ability to address emerging health threats.

### **[Incentives for Immunity — Strategies for Increasing Covid-19 Vaccine Uptake](#)**

Kevin G. Volpp, M.D., Ph.D., and Carolyn C. Cannuscio, Sc.D.

... Incentives alone are unlikely to deliver the population immunity that will end the pandemic. The series of million-dollar jackpots that is being deployed in Ohio is an intriguing alternative to test, but it is unclear whether this will be a widely embraced approach. We need to go further in adopting a combination of behaviorally informed policies that will protect our health and the health of the economy for years to come.

## **Pediatrics**

Vol. 147, Issue 6 1 Jun 2021

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

## **PharmacoEconomics**

Volume 39, issue 6, June 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-6>

### ***Themed issue : Economic Burden of Major Depressive Disorders***

[Reviewed earlier]

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 3 Jul 2021)

[No new digest content identified]

## **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 3 Jul 2021)

**Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial**

Sheila Isanaka, Céline Langendorf, Monica Malone McNeal, Nicole Meyer, Brian Plikaytis, Souna Garba, Nathan Sayinzoga-Makombe, Issaka Soumana, Ousmane Guindo, Rockyiath Makarimi, Marie Francoise Scherrer, Eric Adehossi, Iza Ciglenecki, Rebecca F. Grais

Research Article | published 02 Jul 2021 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003655>

**PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 3 Jul 2021)

[No new digest content identified]

**PLoS One**

<http://www.plosone.org/>

[Accessed 3 Jul 2021]

[No new digest content identified]

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 3 Jul 2021]

[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States of America**

June 15, 2021; vol. 118 no. 24

<https://www.pnas.org/content/118/24>

*Psychological and Cognitive Sciences*

**Worldviews, trust, and risk perceptions shape public acceptance of COVID-19 public health measures**

Michael Siegrist and Angela Bearth

PNAS June 15, 2021 118 (24) e2100411118; <https://doi.org/10.1073/pnas.2100411118>

*Significance*

The successful implementation of measures aimed at reducing the number of people infected with COVID-19 crucially depends on public acceptance of these measures. We show that it is not gender or age but psychological variables, such as trust and worldviews, that strongly influence people's risk perceptions and acceptance of the measures. We are able to show these effects in both cross-sectional and longitudinal study designs. Since the acceptance of implemented measures crucially depends on whether they are in line with people's values and worldviews, the latter two variables are as relevant as epidemiological facts for successful risk management.

**Prehospital & Disaster Medicine**

Volume 36 - Issue 3 - June 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

**Preventive Medicine**

Volume 147 June 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/147/suppl/C>

[Reviewed earlier]

**Proceedings of the Royal Society B**

30 June 2021 Volume 288 Issue 1953

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

**Public Health**

Volume 194 Pages 1-274 (May 2021)

<https://www.sciencedirect.com/journal/public-health/vol/194/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

Volume 13, Issue 3, November 2020

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Reports**

Volume 136 Issue 4, July/August 2021

<https://journals.sagepub.com/toc/phrg/136/4>

[Reviewed earlier]

**Qualitative Health Research**

Volume 31 Issue 7, June 2021

<http://qhr.sagepub.com/content/current>

[Reviewed earlier]

**Research Ethics**

Volume 17 Issue 2, April 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

## **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 3 Jul 2021]

[No new digest content identified]

## **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Selected Articles*

29 Jun 2021

### **Interaction between environmental and socioeconomic determinants for cutaneous leishmaniasis risk in Latin America\***

Original research | English |

29 Jun 2021

### **New Health Sciences Descriptors to classify and retrieve information on equity\***

Current topic |

29 Jun 2021

### **The Health Equity Network of the Americas: inclusion, commitment, and action\***

Current topic | English |

29 Jun 2021

### **Equity and the Cuban National Health System's response to COVID-19\***

Special report | English |

29 Jun 2021

### **The Sustainable Development Goals and Technological Capacity\***

Opinion and analysis | English |

29 Jun 2021

### **Equity, intercultural approaches, and access to information on traditional, complementary, and integrative medicines in the Americas\***

Current topic | English |

## **Risk Analysis**

Volume 41, Issue 6 Pages: 843-1045 June 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 3 Jul 2021]

[No new digest content identified]

**Science**

02 July 2021 Vol 373, Issue 6550

<http://www.sciencemag.org/current.dtl>

[New issue; No digest content identified]

**Science Translational Medicine**

30 June 2021 Vol 13, Issue 600

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

**Social Science & Medicine**

Volume 278 June 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/278/suppl/C>

[Reviewed earlier]

**Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 3 Jul 2021]

[No new digest content identified]

**Theoretical Medicine and Bioethics**

Volume 41, issue 5-6, December 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-5>

[Reviewed earlier]

**Travel Medicine and Infectious Diseases**

Volume 41 May–June 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/41/suppl/C>

[Reviewed earlier]

**Tropical Medicine & International Health**

Volume 26, Issue 6 Pages: i-iv, 609-714 June 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

**Vaccine**

Volume 39, Issue 26 Pages 3455-3536 (11 June 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/26>

*Discussion No access*

**Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests**

Nir Eyal, Tobias Gerhard, Brian L. Strom

Pages 3455-3458

*Research article Abstract only*

**Minimising missed opportunities to promote and deliver immunization services to middle and older age adults: Can hospital-based programs be a solution?**

Kathleen McFadden, Anita Heywood, Amalie Dyda, Jessica Kaufman, Holly Seale

Pages 3467-3472

*Research article Open access*

**Older adolescents and young adults willingness to receive the COVID-19 vaccine: Implications for informing public health strategies**

Tracie O. Afifi, Samantha Salmon, Tamara Taillieu, Ashley Stewart-Tufescu, ... S. Michelle Driedger

Pages 3473-3479

*Research article Open access*

**Older adults' vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake**

Louise A. Brown Nicholls, Allyson J. Gallant, Nicola Cogan, Susan Rasmussen, ... Lynn Williams

Pages 3520-3527

*Research article Abstract only*

**Patient and clinician factors associated with uptake of the human papillomavirus (HPV) vaccine among adolescent patients of a primary care network**

Julie H.T. Dang, Susan L. Stewart, Dean A. Blumberg, Hector P. Rodriguez, Moon S. Chen

Pages 3528-3535

**Vaccines — Open Access Journal**

<http://www.mdpi.com/journal/vaccines>

[No new digest content identified]

**Value in Health**

Volume 24 Issue 6 p753-916

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

\*

\*

\*

\*

**Media/Policy Watch**

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers,

magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The sheer volume of vaccine and pandemic-related coverage is extraordinary. We will strive to present the most substantive analysis and commentary we encounter.

### **The Atlantic**

<http://www.theatlantic.com/magazine/>

*Accessed 3 Jul 2021*

[No new, unique, relevant content]

### **BBC**

<http://www.bbc.co.uk/>

*Accessed 3 Jul 2021*

[No new, unique, relevant content]

### **The Economist**

<http://www.economist.com/>

*Accessed 3 Jul 2021*

*After the disease*

#### **The long goodbye to covid-19**

**The pandemic is still far from over, but glimpses of its legacy are emerging**

Jul 3, 2021

WHEN WILL it end? For a year and a half, covid-19 has gripped one country after another. Just when you think the virus is beaten, a new variant comes storming back, more infectious than the last. And yet, as the number of vaccinations passes 3bn, glimpses of post-covid life are emerging. Already, two things are clear: that the last phase of the pandemic will be drawn-out and painful; and that covid-19 will leave behind a different world...

### **Financial Times**

<https://www.ft.com/>

*Coronavirus latest: Fourth of July travel projected to near record high*

#### **Brazil's top prosecutor opens investigation into Bolsonaro over vaccine deal**

July 2, 2021

*Coronavirus latest: Michigan's \$5m vaccine lottery draws 500,000 applicants in first day*

#### **Michigan's \$5m vaccine lottery draws 500,000 applicants in first day**

July 2, 2021

*Coronavirus: White House sets up 'surge response teams' to tackle Delta hotspots - as it happened*

#### **Africa's head of vaccine procurement hits out at EU for hoarding jabs**

July 1, 2021

### **Forbes**

<http://www.forbes.com/>  
Accessed 3 Jul 2021  
[No new, unique, relevant content]

**Foreign Affairs**  
<http://www.foreignaffairs.com/>  
Accessed 3 Jul 2021  
[No new, unique, relevant content]

**Foreign Policy**  
<http://foreignpolicy.com/>  
Accessed 3 Jul 2021  
[No new, unique, relevant content]

**New Yorker**  
<http://www.newyorker.com/>  
Accessed 3 Jul 2021  
[No new, unique, relevant content]

**New York Times**  
<http://www.nytimes.com/>  
Accessed 3 Jul 2021  
*World*  
[\*\*These are the U.S. states trying lotteries to increase Covid vaccinations.\*\*](#)  
By Adeel Hassan and Andrea Kannapell 3 July 2021

*Middle East*  
[\*\*Iran's president warns of a potential fifth wave as the Delta variant spreads.\*\*](#)  
By Jesus Jiménez 3 July 2021

*Americas*  
[\*\*Brazil Vaccine Scandal Imperils Bolsonaro as Protests Spread\*\*](#)  
Brazilians were angry over how slowly their government moved to acquire coronavirus vaccines. Now they're incensed over a corruption scandal involving vaccine deals.  
By Ernesto Londoño and Flávia Milhorance 3 July 2021

**Washington Post**  
<https://www.washingtonpost.com/>  
Accessed 3 Jul 2021  
[No new, unique, relevant content]

\* \* \* \*

***Think Tanks et al***

**Brookings**  
<http://www.brookings.edu/>

Accessed 3 Jul 2021

TechTank

## [\*\*Vaccine passports underscore the necessity of U.S. privacy legislation\*\*](#)

Nicol Turner Lee, [Samantha Lai](#), and [Emily Skahill](#)

Monday, June 28, 2021

**Center for Global Development** [to 3 Jul 2021]

<http://www.cgdev.org/page/press-center>

Publication

## [\*\*Plus ça change: COVID-19 and Its Collateral Impact during the Vaccine Era\*\*](#)

July 1, 2021

Over the past year we partnered with researchers in Kenya, the Philippines, South Africa, and Uganda to document, from a [whole-of-health perspective](#), what we know about the nature, scale, and scope of COVID-19's disruptions to essential health services in those countries, and the health effects of such disruptions. In a [working paper released today](#), we build on a [blog we published in March](#) when we released working papers from each country team (the papers are available here: [Kenya](#), [the Philippines](#), [South Africa](#), [Uganda](#)). In this new working paper, we summarize the results and lessons across the four countries in more detail. We also tie together many of the blogs we have written on this topic over the past year (this series of blogs can be found [here](#)).

Damian Walker et al.

**Chatham House** [to 3 Jul 2021]

<https://www.chathamhouse.org/>

Accessed 3 Jul 2021

[No new digest content identified]

**CSIS**

<https://www.csis.org/>

Accessed 3 Jul 2021

Blog Post

## [\*\*Covid-19's Toll on Youth in Southeast Asia\*\*](#)

July 2, 2021

Podcast Episode

## [\*\*Richard Hatchett on CEPI in the Covid-19 Era\*\*](#)

July 1, 2021 | By [J. Stephen Morrison](#)

Transcript

## [\*\*CEPI 2.0: A Critical Inflection Point\*\*](#)

June 29, 2021

Transcript

## [\*\*The Reality of Rolling Out COVID-19 Vaccines\*\*](#)

June 29, 2021

*Commentary*

## **The CPTPP and Intellectual Property Rights Protection**

June 28, 2021 | By [Joanna Shelton](#)

### **Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

June 30, 2021 *News Release*

### **Workers Are More Likely to Get a COVID-19 Vaccine When Their Employers Encourage It and Provide Paid Sick Leave, Though Most Workers Don't Want Their Employers to Require It**

A Third of Parents with Kids Ages 12-17 Report Their Kids Are Now Vaccinated; Most Parents Oppose Mandatory Vaccinations for School Children As more employers return to in-person work, the latest KFF COVID-19 Vaccine Monitor report shows that workers are more likely to have gotten a COVID-19 vaccine when their...

**Urban Institute** [to 3 Jul 2021]

<https://www.urban.org/publications>

*Publications*

### **COVID-19 Vaccine Attitudes among Nonelderly Adults Who Reported Being Unlikely to Get Vaccinated**

Adults' decisionmaking about getting the COVID-19 vaccines is complex. This brief provides qualitative insights from interviews conducted in February 2021 with 40 nonelderly adults who reported in the Urban Institute's December 2020 Well-Being and Basic Needs Survey (WBNS) that they would probably or definitely not get a COVID-19 vaccine. Our key findings are as follows: As of February 2021, most interviewees

Dulce Gonzalez, Haley Samuel-Jakubos, Brigitte Courtot, Clara Alvarez Caraveo, Joshua Aarons

June 21, 2021

Brief

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

*Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).*

*Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.*

\* \* \* \*